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Abstract 
Background: Stroke and cancer are both leading causes of death and disability in the 
Western world. Cancer can lead to a hypercoagulable state that can cause ischemic 
stroke. Mechanisms include disturbance of the coagulation cascade, tumor substance 
secretion, infections and non-bacterial endocarditis. Many types of cancer also share 
a similar risk factor profile to that of ischemic stroke. The cancer-stroke connection 
has not previously been studied in Norway. Further knowledge on which subgroups 
of patients are at highest risk for both stroke and cancer, as well as on how to 
recognize a cancer-associated stroke is needed. 
Methods and materials: The studies 1-3 are the foundation of the present thesis. All 
papers have used data from The Norwegian Stroke Research Registry 
(NORSTROKE). NORSTROKE is a comprehensive, prospective registry that since 
February 2006 has included all stroke patients admitted to the Stroke Unit at 
Haukeland University Hospital. For the present studies, the medical charts of all 
stroke patients were reviewed for collection of cancer diagnoses. Cancer data was 
quality assured through linking NORSTROKE to The Cancer Registry of Norway.  
Results: From August 2006 through August 2011, 1511 patients with ischemic stroke 
were registered in NORSTROKE. In study I, patients with cancer post stroke were 
excluded. In study I, a total of 1456 patients were included, of whom 229 (15.7 %) 
had cancer prior to index stroke. The prevalence of stroke was higher in stroke 
patients compared to the general population below the age of 70. 
In study II, patients with cancer pre stroke were excluded. In study II, a total of 1282 
patients were included, of whom 55 (4.3 %) were diagnosed with cancer post index 
stroke. In study III, the inclusion period was extended and patients with inactive 
cancer were excluded. In study III, 1646 patients were included in the study, of whom 
82 (5.0 %) had active cancer.  
The most common cancer types overall were cancer of the; colon, prostate, breast, 
lung, bladder, uterus and ovaries as well as of unknown primary site. Patients with 
active cancer had similar risk factors to patients without a history of cancer. Active 
cancer in stroke patients was associated with smoking, age, increased D-dimer and 
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decreased hemoglobin. Active cancer was also associated with stroke of unknown 
etiology. 
Conclusions: The prevalence of cancer was higher in stroke patients compared to the 
general population below the age of 70. Findings in patients with cancer-associated 
ischemic stroke were elevated D-dimer, signalling hypercoagulation, lower 
hemoglobin and a history of smoking. These factors may also be used to predict 
active cancer in stroke patients and thus indicate which stroke patients could be 
screened for underlying cancer.  
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The brain as an organ is in many ways still a great mystery. Millions upon millions of 
neurons fire in an intricate network to shape our thoughts, our actions and our very 
sense of being. It can seem quite surreal that this grey, gelatinous matter is not only 
what gives us feelings, enables reason and reflections, gives us hopes and ambitions, 
creates the perception of our surroundings, but also what defines us as a species.  
In neuroscience this is referred to as The Binding Problem;1-5 the lack of explanation 
for how the electronic firings of the neurons all come together, shaping our 
consciousness.  
There are endless unanswered questions regarding the brains workings, potential for 
rehabilitation and plasticity.6-9 One thing is however certain; if the brain is damaged 
or impaired, it is often striking, and for a patient with functions temporarily or 
permanently lost, it can be life altering. The brain holds our personality and maintains 
our abilities. In order to uphold these defining functions, the brain requires constant 
blood flow for supply of oxygen and energy. Even brief disruptions in blood flow can 
have grave consequences, which is often the case in an ischemic stroke. 
 
The foundation for the following thesis 
While working in the Stroke Unit at Haukeland University Hospital, Professors Næss 
and Thomassen observed that a number of ischemic stroke patients had a medical 
history that included cancer. For some ischemic stroke patients, cancer was first 
diagnosed during the stroke work-up in the Stroke Unit. This founded the hypothesis 
for this project and thesis; cancer is a risk factor for ischemic stroke.  
While cancer can cause hypercoagulability, leading to ischemic stroke, ischemic 






Definition of ischemic stroke
The classic definition of stroke from the World Health Organization (WHO) was 
“rapidly developing clinical signs of focal (or global) disturbance of cerebral 
function, with symptoms lasting 24 hours or longer or leading to death, with no 
apparent cause other than of vascular origin”.11 However, the definition is under 
constant review as stroke science, diagnostics and imaging techniques are changed 
and improved. Stroke has later been defined as neurological symptoms or deficit 
lasting >24 h or transient ischemic attacks where CT or MRI shows infarctions 
related to the clinical findings.12 
The most recent consensus on defining stroke from the American Heart 
Association/American Stroke Association provides a broader definition and is shown 




Table 1. Definition of stroke. 
The term “stroke” should be broadly used to include all of the following definitions of: 
Central Nervous System (CNS) infarction: CNS infarction occurs after brain, spinal cord, or retinal 
cell death attributable to ischemia, documented by 
1. pathological imaging, or other objective evidence of cerebral, spinal cord, or retinal focal ischemic 
injury in a defined vascular distribution; or 
2. clinical evidence of cerebral, spinal cord, or retinal focal ischemic injury based on symptoms 
persisting ≥24 hours or until death, and other etiologies excluded. 
Ischemic stroke: An episode of neurological dysfunction caused by focal cerebral, spinal, or retinal 
infarction.  
Silent CNS infarction: Imaging or neuropathological evidence of CNS infarction, without a history of 
acute neurological dysfunction attributable to the lesion. 
Intracerebral hemorrhage: A focal collection of blood within the brain parenchyma or ventricular 
system that is not caused by trauma. 
Stroke caused by intracerebral hemorrhage: Rapidly developing clinical signs of neurological 
dysfunction attributable to a focal collection of blood within the brain parenchyma or ventricular 
system that is not caused by trauma. 
Silent cerebral hemorrhage: A focal collection of chronic blood products within the brain 
parenchyma, subarachnoid space, or ventricular system on neuroimaging or neuropathological 
examination that is not caused by trauma and without a history of acute neurological dysfunction 
attributable to the lesion. 
Subarachnoid hemorrhage: Bleeding into the subarachnoid space (the space between the arachnoid 
membrane and the pia mater of the brain or spinal cord). 
Stroke caused by subarachnoid hemorrhage: Rapidly developing signs of neurological dysfunction 
and/or headache because of bleeding into the subarachnoid space (the space between the 
arachnoid membrane and the pia mater of the brain or spinal cord), which is not caused by trauma. 
Stroke caused by cerebral venous thrombosis: Infarction or hemorrhage in the brain, spinal cord, or 
retina because of thrombosis of a cerebral venous structure. Symptoms or signs caused by reversible 
edema without infarction or hemorrhage do not qualify as stroke. 
Stroke, not otherwise specified: An episode of acute neurological dysfunction presumed to be 
caused by ischemia or hemorrhage, persisting ≥24 hours or until death, but without sufficient 
evidence to be classified as one of the above. 
 
Adapted from Sacco et al., Stroke, 2013.13 
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Stroke pathophysiology – time is of the essence  
In an ischemic stroke (IS), the patient suffers a cerebral infarction as a result of the 
disruption of blood supply to a part of the brain. This disruption is caused by 
hypoperfusion or obstruction; either from local thrombosis, emboli, severe stenosis 
due to atherosclerosis, inflammation, dissection or other causes. Estimates show that 
87 % of all strokes are ischemic, whereas 10 % are haemorrhagic strokes, the result 
of a spontaneous intracerebral haemorrhage (ICH), and approximately 3 % are caused 
by subarachnoid haemorrhage (SAH).14 If a patient has clinical symptoms of a stroke 
that subside within 24 hours, imaging is normal and differential diagnoses have been 
ruled out, the patient has likely suffered a transient ischemic attack (TIA). In a TIA, 
the blood supply to part of the brain is temporarily obstructed. TIA can be an early 
warning sign of an ischemic stroke, and a comprehensive review study show that TIA 
patients have a risk from 0.9 to 11.0 % of suffering an ischemic stroke within one 
week, depending on access to emergency care and specialist stroke services, and 
should be treated urgently.15 For the following year after TIA, the patients have a  
5.1 % risk of stroke.16 In contrast to a TIA, an IS causes permanent damage to the 
brain due to severe disruption of blood flow; an infarction is established. The term 
infarction is derived from the Latin word “infarctus”,17 which means “stuff into”. 
Ischemic tissue will through the disruption of blood supply have an oxygen 
deprivation, to the extent of metabolic demand no longer being feasible. The 
pathological lack of oxygen and nutrients will cause excitotoxicity, mitochondrial 
alterations, oxidative stress from free radicals and protein misfolding, as well as an 
inflammatory response.18 Cells in the infarcted area will be unable to uphold cell 
homeostasis and affected neurons, endothelial cells and surrounding glia will be 
injured or die.  
Even though our brain only constitutes about 2 % of our body weight, it requires 
approximately 20 % of total oxygen consumption.19, 20 Within minutes without 
oxygen, neurons will start to die. Collateral circulation to the area with restricted 
blood supply will often determine the final size of the infarcted area.  
However, collaterals may shut down as processes are dynamic; especially in the acute 
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phase after infarction. Also, the peripheral zone of the infarction, the penumbra, can 
survive the stroke if reperfusion is rapid. Predicting the exact size of the infarcted 
area is therefore quite difficult. Though time is indicative of the progression of 
pathophysiological processes, growth of the infarction in the acute phase is dynamic, 
and shows great inter-individual variability.21, 22  
When a stroke occurs, the expression “time is brain” is used with due cause. Humans 
are born with an average of 90 billion neurons,23 and in an untreated ischemic stroke, 
up to 2 million neurons die per minute.24 Thus, after initiating acute stroke treatment 
and intervention, immediate transportation to a comprehensive stroke center is 
crucial, in order to ensure the best and fastest recanalization possible. 
 
Acute stroke treatment and management 
The main goal of stroke treatment is early recanalization. Penumbral tissue, still alive 
and within the threshold of cell homeostasis, is located in the peri-infarct area and is 
still salvageable.25-27 Acute ischemic stroke treatment comprises intravenous (IV) 
thrombolysis with tissue plasminogen activator (tPA) and endovascular treatment 
(EVT). Thrombolytic agents convert plasminogen into plasmin, the primary 
fibrinolysin; thereby instigating lysis of the occluding thrombus (Figure 2).28, 29   
The IV tPA alteplase, Actilyse ®, was approved for stroke treatment by the American 
Food and Drug Administration in 1996, whereas the Norwegian Medicines Agency 
first approved it as standard stroke treatment in 2003. Today, other tPAs, such as 
tenectaplase, Metalyse ®, have been tested for use in acute stroke with promising 
results. All stroke patients in the present thesis received the thrombolytic agent 
alteplase if thrombolysis was indicated. 
The ground-breaking “National Institute of Neurological Disorders and Stroke rt-PA” 
(NINDS) and European Cooperative Acute Stroke Study (ECASS) trials in 1995 
proved the benefit of thrombolytic treatment within 3 hours post stroke onset.30 
However, since ECASS III in 2008, 4.5 hours has been the accepted treatment 
window.31, 32 ,33 Even though IV tPA treatment can be administered up until 4.5 hours, 
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faster treatment leads to better clinical outcome.32 Hence the focus on so-called door-
to-needle time (DNT); the time from an IS patient’s arrival to the Emergency 
Department (ED) to administration of IV tPA. Demonstrating just how time-critical 
thrombolysis treatment is, the thrombolysis review by Meretoja et al in Stroke from 
2014 concluded with “save a minute save a day”. They showed that for each minute 
the DNT was reduced, patients gained an average of 1.8 days of disability-free life.34  
IV tPA alone is not always successful in obtaining recanalization, especially when a 
larger blood clot is located in a branch of a main artery. EVT can, when indicated, 
provide a more effective revascularization and better clinical outcome.35-37 In 2015, 
the results of five major EVT-trials were published, proving EVT’s efficacy and 
safety.35 EVT consists of thrombectomy with or without intra-arterial (IA) 
thrombolysis, and thrombectomy is today the recommended standard of care for IS 
patients with large vessel occlusion (LVO) in the anterior circulation.35, 38, 39 EVT is 
also performed for occlusions in the posterior circulation on a case by case basis. 
Posterior occlusions often entail fatal outcomes with or without EVT, and the chosen 
treatment is therefore varied.40-42  
EVT procedures will likely increase dramatically in the coming years, as the recently 
published DAWN trial demonstrated an effect of EVT up to 24 hours after stroke 
onset in selected patients.38, 43-45 After the implementation of EVT in stroke treatment, 
the consensus has turned into “save a minute save a week”, since it has been shown 
that reducing the stroke onset to thrombectomy time by a minute could give a patient 
an extra 4.2 days of disability-free life.46 
Ideally, all IS patients should be transported directly to a comprehensive stroke center 
that offers tPA, as well as EVT, when indicated. However, due to geographical and 
resource limitations, this is not always feasible. This is when the so-called “Drip and 
ship” method is used.47 Thrombolytic treatment is then initiated, the drip, prior to 
transport to a stroke center for possible endovascular treatment, hereby using IV tPA 
as bridging and starting acute treatment with the aim of removing the clot. 
The last stance of stroke treatment will for certain patients be a decompressive 
hemicraniectomy (DHC). When an MCA infarction causes edema, leading to 
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malignant increase of the intracerebral pressure, a malignant infarction with an 
ensuing 80 % mortality occurs. Of all stroke patients, about 10 % will suffer from the 
potentially fatal malignant infarction.48 DHC avoids herniation and consequently 
reduces mortality in these patients.49, 50 
No matter what acute stroke treatment is initially chosen by the on-call neurologist 
and intervention radiologist in the ED, all stroke patients admitted to Haukeland 
University Hospital are transferred to the Stroke Unit for observation and continued 
treatment to restore and maintain homeostasis. Stroke progression and symptoms are 
monitored by use of repeated scores with the National Institutes of Health Stroke 




Cardiovascular risk factors 
Stroke and other cardiovascular diseases (CVD) have a high prevalence and 
incidence and are affected by several risk factors. CVD risk factors are dichotomized 
as modifiable and non-modifiable risk factors. Examples of non-modifiable risk 
factors are age, sex, genetic disposition and ethnicity. Modifiable risk factors are 
often affected by the environment and socioeconomic status (SES), but can be 
influenced through choices of lifestyle.51 Some environmental, modifiable risk 
factors, such as air pollution,52 are influenced by governmental policy more than the 
choices of the individual.53 The traditional CVD risk factors are hypertension (HT), 
hyperlipidemia (HL), diabetes mellitus (DM), atrial fibrillation (AF), coronary artery 
disease (CAD), peripheral artery diseases (PAD) and carotid stenosis, obesity, 
physical inactivity, poor diet, and smoking. 54-56 
Risk factors that have not yet been documented as thoroughly are migraine, metabolic 
syndrome, heavy alcohol consumption, drug abuse, sleep-disordered breathing, 
hyperhomocysteinemia, inflammation and infection, and finally, hypercoagulability, 
including an acquired hypercoagulable state.54 
Epidemiological studies have shown us that the risk of CVD increases with each 
added risk factor, and that risk factors not only appear in clusters, but also have the 
ability to potentiate each other.57 For instance, for patients with DM type 2, the risk of 
cardiovascular complications is somewhere between 2- 4 times higher than in a 
healthy person.58  
Stroke risk factors vary greatly between age strata and stroke etiologies.59-61 Stroke is 
in no way a strictly geriatric disease, as also children may suffer stroke. Age 
nevertheless remains the most important risk factor for ischemic stroke in adults. 
Approximately 60 % of all stroke patients are above 75 years of age when they suffer 
their first stroke.62  
A recent large-scale study comparing stroke risk factors globally, found that 90 % of 
all stroke cases are associated with ten modifiable risk factors.63 Many of these are 
also risk factors for cancer. 
 20 
Shared risk factors for CVD and cancer 
Many risk factors are important in both ischemic stroke and cancer causality. These 
include risk factors on a macro level, such as air pollution,64 to the micro level of the 
inflammatory response of our immune system to various stimuli.  
Because CVD and cancer share risk factors, the WHO now recommends that we 
direct preventative efforts at CVD and cancer conjointly.65 The four modifiable risk 
factors that have gained special attention are diet, sedentary lifestyle, tobacco use and 
obesity.66 Recent evidence shows that CVD and cancer have pathophysiological 
factors in common and that these factors can cause both disease entities.67 The shared 
biology of the risk factors is mainly through inflammation and oxidative stress.10 
Obesity, hyperglycemia, hyperlipidemia, hypertension, alcohol consumption, tobacco 
use, as well as other chronic diseases, all induce inflammation. 68 Inflammation 
mediates all stages of atherosclerosis, including thrombosis, and also promotes 
carcinogenesis and tumor progression.10 Inflammation is also known to induce 
oxidative stress and reactive oxygen species, another biological factor shared by CVD 
and cancer.69 Oxidative stress and its free radicals can alter lipids, proteins and DNA, 
and is seen in pathogenesis of cancers, atherosclerosis as well as inflammation.70 
 
Tobacco use 
Smoking is the primary cause of the most harmful non-communicable diseases 
(NCDs) globally; cancer, CVD, diabetes and chronic respiratory disorders.53 Smoking 
was responsible for over 100 million deaths in the 20th century, and therefore has 
smoking cessation been a global public health target. Less smoking has resulted in an 
overall tobacco reduction in the past decade, also in Norway.71 This will lower the 
risk of CVD and stroke, albeit, not with immediate effect. Smoking has a so-called 
delayed disease burden, thus in cancer epidemiology it takes three decades to see a 
reduction in lung cancer rates after smoking cessation.66  
In the Nordic countries where snuff (smokeless tobacco) is in large replacing prior 
smoking, it can be speculated if we will see snuff use as a shared risk factor in the 
future. At present, the epidemiological studies of snuff and health outcomes have 
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found no increased risks for long-term morbidity or mortality connected to snus-
use.72 However, similar to smoking, snuff gives a temporary increase in blood 
pressure, and should therefore be used by caution by patients with known CVD.73 
Tobacco products in general contain nicotine that leads to a vasoconstriction of blood 
vessels and increases the blood pressure. Smoking is also proinflammatory.  
The combustion reaction in smoking will also create carbon monoxide and 
nitrosamines, known carcinogens, and other oxidizing agents. Toxic to the cardio-
respiratory system, they increase the risk of CVD and lung cancer, as well as the risk 
of other cancer types, such as cancer of the larynx, kidneys, esophagus, stomach, oral 
cavity and bladder, as well as acute leukemia.53 Nicotine has also been shown to 
enhance angiogenesis and inhibit apoptosis.74 
 
Obesity  
Alarmingly, more than one third of the adult population is obese.75 Obesity increases 
the risk for both cardiovascular and cancer, as well as mortality from both diseases. 
Epidemiological studies show that up to 20 % of all cancers are related to obesity,76 
and the risk of cancer increases with an increasing body mass index (BMI). Obesity 
has now been linked to cancer of the pancreas, colon, breast, liver, endometrial, 
kidneys, and esophageal adenocarcinoma.10 The connection between obesity, CVD 
and cancer is especially intricate compared to other risk factors as obesity fosters 
other traditional CVD risk factors like metabolic syndrome, DM, HT, HL and 
hyperglycemia. Moreover, the other modifiable risk factors, such as physical activity 
and diet, greatly determine the degree of obesity and vice versa. Adipose tissue 
produces hormones and cytokines that may have altering effects on metabolic 
functions.  Hormones, like leptin and insulin-like growth factor (IGF), and 
adipokines, cytokines from adipose tissue, can be proinflammatory and 
prothrombotic,77 as well as have tumorigenic effects. The cytokine produced at the 
highest rate by adipose tissue is interleukin-6 (IL-6), which instigates hypertension. 
IL-6 also stimulates the liver to produce C-reactive protein (CRP). It has been shown 




A sedentary lifestyle is a risk for cancer and CVD, as well as for other CVD risk 
factors like obesity, DM, HT and HL. Regular exercise can decrease the incidence of 
cancer, specifically, cancer of the colon, breast and endometrium, and reduce the risk 
of cardiovascular disease.79 Exercise has many positive effects; from strengthening 
our skeleton to maintaining the functions of our vessel musculature. Again 
overlapping with the other risk factors, living a sedentary lifestyle disposes obesity 
and thus adipose tissue increase, with its production of proinflammatory and 
prothrombotic cytokines and hormones, insulin and leptin.  
 
Diet and alcohol 
The link between diet and CVD risk is well established, but the link is, like obesity, 
facilitated by other CVD risk factors such as BMI, HT and level of serum lipids. 
Consensus from the World Heart Federation is that a good diet, with the lowest risk 
of leading to CVD or cancer, is high in fruits, vegetables, whole grains, legumes, fish 
and nuts.80 A diet often recommended is therefore the Mediterranean diet because it is 
low in sugar, saturated fats and sodium. A Mediterranean diet can decrease the risk of 
cancer, such as colon cancer, and also provide cardiovascular protection.81 A linear 
relationship between red meat consumption and colon cancer has recently been 
shown,82 while the colon cancer risk decreases with a diet high in fruits and fiber. The 
colon cancer risk is hypothesized to result from chronic inflammation. Low folate 
intake increases the risk of CVD and cancer, and lack of folate has been shown to 
contribute in the atherosclerosis pathogenesis. Intake of polyphenols, found in fruits 
and vegetables, have also been shown to protect against CVD and cancer.83 
Polyphenols are micronutrients with antioxidant properties.84 Alcohol in moderate 
quantities, in otherwise healthy persons, has been postulated to be CVD-protective. 
This is also due to alcohol’s polyphenol content and polyphenols’ effect of decreased 
inflammation and antithrombotic capacities.85, 86 Higher alcohol consumption is on 
the contrary associated with increased CVD and CVD mortality, as well as cancers of 
the entire gastrointestinal tract, liver, larynx and breast.10 Alcohol has been associated 
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with triggering AF, inducing HT, increased triglycerides and polymorphisms in the 
genes; thus linking alcohol to both CVD and cancer. 87 
 
Diabetes mellitus 
Diabetes mellitus (DM) is known as one of the traditional CVD risk factors because it 
effects the macro- and microvasculature. With the increasing incidence of obesity, the 
incidence of DM type II also increases. DM is linked to development of 
atherosclerosis through insulin resistance and hyperglycemia causing endothelial 
dysfunction and dyslipidemia.10  
In the last decades, studies have also shown that DM is associated with cancer of the 
colon, breast, liver, pancreas, endometrium and bladder. 88 DM causes inflammation 
through hyperglycemia, hyperinsulinemia and IGF, which contributes to CVD 




The cancer-stroke connection  
Definition of cancer  
Cancer is by definition an uncontrolled and continuous division of cells, from any 
tissue or place in the body.89 In a healthy individual, cell functions, cell division 
included, are strictly regulated through cell signals; certain signals induce an action or 
process, others suppress it. A cancerous cell has become autonomous and is therefore 
no longer stimulated by the natural cell signals and regulations. The cancer cells have 
undergone multiple mutations increasing exponentially with every division. Often, 
these mutations provide the cancer cells with the ability to override any signal of 
apoptosis, the programmed cell death.90 Avoiding apoptosis permits the uncontrolled 
growth. 
When a solid cancer develops, it breaks through the basal membrane of the 
epithelium, no longer respecting its natural boundaries. First it becomes an invasive 
tumor which invades nearby tissue. Thereafter the invasive tumor will shed cancer 
cells that spread to distant sites through the lymph – or blood vessels. These shed 
cells may induce growth of new tumors, metastasize, depending on metastasis-
progression genes and expression.91 The development of solid cancer is portrayed in 
Figure 1. For cancers of the blood or bone marrow, the development is different, but 
still a result of a series of mutations.92 
There are more than one hundred different types of cancer, yet some occur more 
frequently than others.89 Globally, the cancers with the highest incidence are breast 
cancer, pulmonary cancer (including tracheal, bronchus and lung cancer), colorectal 
cancer, prostate cancer, stomach cancer, gynecological cancer (including ovarian, 
uterine and cervical cancer), liver cancer, Non-Hodgkin lymphoma and leukemia.93 
The incidence of each cancer type various greatly between countries, and depends 
both on genetics and risk factors.94 Any incidence will also be contingent on the 
infrastructure of the local healthcare system; for example if registration of diagnoses 
is mandatory or voluntary. 
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Cancer can affect the body’s homeostasis and organs in a many ways. Cancer cells 
may invade and physically impede the normal function if the tissue, or the presence 
of cancer cells can induce a cellular response from otherwise healthy cells as part of a 
host defense.95 
Moreover, cancer cells can produce and secret substances, such as enzymes or 
cytokines. This may interrupt other natural processes and cycles, for instance by 
suppressing the immune system and defense. 96 Hence, an invasive cancer may cause 
multiple reactions in itself or through host-response, which in turn induces 
responding cascades that may lead to a malignant domino effect. 
Cancer can also affect coagulation and lead to ischemic stroke, which is the scientific 
foundation of the present thesis.  
 




Adapted from “3 Stages of Cancer Development”, accessed Jan. 9, 2018.97  
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The pioneer in cancer-associated stroke 
In 1865 Armand Trousseau (1801 – 1867) was the first to write about a connection 
between stroke and cancer.98 Working at the hospital l`Hõtel-Dieu in Paris, France, 
Professor Trousseau noticed that cancer patients often suffered migratory 
thrombophlebitis; recurrent venous thrombosis.99 These extraordinary findings were 
first presented in his lecture named “‘Phlegmasia Alba Dolens”.100  
Most importantly, he discovered that thrombotic events often preceded the clinical 
manifestation and diagnosis of cancer, thus pioneering the thought of investigating 
for cancer in the presence of idiopathic thrombosis.101 Trousseau Syndrome became 
the first term of cancer-associated thromboembolism. Professor Trousseau insisted 
that the thromboembolism was not due to mechanical obstruction in the blood vessel, 
but due to tumor-related alterations of the hemostatic system itself.100 This is 
important because it provides the basis for cancer causing ischemic stroke; arterial 
thromboembolism, and also venous embolisms. 
As fate would have it, Professor Trousseau later diagnosed himself with Trousseau 
Syndrome upon discovering that he himself suffered from gastric cancer.100, 102 Upon 
diagnosis of thromboembolism in his left arm, he famously said to his medical 
students: “I am lost; I have no doubt about the nature of my disease”. He passed away 
from his cancer at the age of 66 years.  
 
Graus et al. break new ground  
Two English doctors, Matheson and James, published a cohort study in 1935, 
confirming Professor Trousseau’s findings.100 However, further research on the 
cancer-stroke connection was scarce until Graus et al. published an extensive autopsy 
study on the topic in 1985.  
In this study, they completed 3426 autopsies of patients with non-CNS cancer. The 
results demonstrated that 15% of cancer patients suffered cerebrovascular disease 
during the course of their cancer disease. However, only about 50% of these patients 
had documented and diagnosed clinical symptoms of stroke during their lifetime. 103 
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Graus et al. suggested retrospectively that this was because the clinical symptoms of 
stroke in cancer patients were more diffuse, and less often focal. 
Stroke is the second most common neurological disease in cancer patients, surpassed 
in numbers only by cancer metastasis to the nervous system.103, 104 As such, we know 
that systemic cancer provides an increased risk of stroke.105, 106 
Cancer itself, as well as cancer treatment, may lead to a hypercoagulable state, 
causing ischemic stroke.105, 107-111 In a hypercoagulable state the patient has an 
abnormal and increased tendency to create blood clots or thromboemboli, as well as 
reduced fibrinolysis.112, 113 A hypercoagulable state has been defined as “any 
prothrombotic condition caused by a specific disorder of blood coagulation”.114  
There are numerous causes to hypercoagulable states, some are genetic while others 
are acquired. Cancer is one of the most common causes of an acquired 
hypercoagulable state.115, 116 Mechanisms include disturbance of the coagulation 
cascade, tumor mucin secretion, infections and non-bacterial endocarditis.104, 117-120   
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Causes of cancer-associated stroke 
Another benchmark study in the field of cancer-associated hypercoagulation and 
subsequent stroke, is the review by Grisold et al. from 2009.118 They presented the 
following main causes of cancer-associated stroke: 
 
- Coagulation disorders; including hypercoagulable state, disseminated 
intravascular coagulation (DIC; most often in metastatic and hematological 
cancer), Non-bacterial Thrombotic Endocarditis and reduced fibrinolysis. 
- Tumor related factors; including direct tumor effect (tumor embolism, vessel 
infiltration or compression), intravascular lymphoma (a diagnosis most often 
made on autopsy) and hyper-viscous obstructions due to hematological cancer. 
- Infections (sepsis can be associated with DIC). 
- Therapy-related; including chemotherapy, surgical complications and post-
radiation vasculopathy (especially in relation to head- and neck cancer). 
 
The latest major review on cancer-associated strokes was published in 2014.109 In this 
review, Dearborn et al. presented the most common mechanisms of cancer-related 
stroke published in recent years (table 2).  




Table 2. Potential Mechanisms of Cancer-Related Stroke. 
Mechanism Causal factor Associated tumors Stroke 
Characteristics 
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Hypercoagulability- the pathogenesis 
Despite more than a century passing since Trousseau discovered cancer-associated 
thrombosis, the pathophysiology behind the hypercoagulable state is still poorly 
understood.121 Thereby is also the pathway from cancer-induced hypercoagulation to 
ischemic stroke remaining unclear. However, certain factors have been unveiled.  
Cancer cells can express procoagulant factors themselves,122, 123 or they can stimulate 
healthy cells to secrete procoagulant factors.124 This means that tumor cells affect 
homeostasis and the coagulation cascade from different target points; both directly, 
by producing for instance thrombin (factor II), and indirectly through affecting 
healthy cells.  
The two cancer cell substances with prothrombotic abilities that have been isolated 
and sufficiently characterized are cancer procoagulant (CP) and tissue factor (TF).125-
130 CP is a Vitamin K-dependent cysteine protease that activates factor X of the 
coagulation cascade directly (Figure 2). CP has also been shown to activate platelets 
in a similar fashion to that of thrombin.131 CP is, unlike TF, not found in normal, 
differentiated tissue.132 
TF is a transmembrane glycoprotein found on the surface of many cells, both normal 
and tumor cells, and is also known as coagulation factor III. TF is a primary initiator 
of clotting by way of the coagulation cascade (Figure 2). TF will, through the so-
called extrinsic pathway of the coagulation cascade, form a complex together with 
factor VII. This complex will activate factors IX and X; coagulation has been 
initiated. The expression of TF on the tumor cell surface has been shown to be 
linearly correlated with the malignancy and histological grade of tumors.133 Higher 
histological grades have a higher TF expression.  
Circulating tumor cells (CTCs) produce TF and procoagulant factors like other tumor 
cells, but they can also cause formation of coagulation factor-complexes on their cell 
surfaces, another way of activating coagulation.134 Circulating microparticles are 
small fragments shed from endothelial cells, leucocytes or tumor cells. They are often 
saturated with TFs, and are known to initiate both inflammation and thrombosis.134 
Cancer cell-derived extracellular vesicles (EVs), a form of microparticles, also 
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contribute to the cancer-induced hypercoagulable state. Recently it was shown that 
EV-induced coagulopathy can be independent of TF, though both TF and EV are 
often found in high quantitates in the same cancer patients.135  
Malignancies also have another indirect way of affecting coagulation; i.e. by 
inhibiting endogenous anticoagulation. Tumor cells cause endothelial cells and 
platelets to upregulate their production of plasminogen activator inhibitor-1 (PAI-1). 
PAI-1 is a protein that functions as our main physiological inhibitor of tPA. 
Upregulation of PAI-1 therefore inhibits fibrinolysis. Inflammation can also induce 
PAI-1generation by stimulating monocytes and endothelial cells.136  
Cancer can induce a systemic response in the body, similar to that in inflammatory 
disease or infection, causing release of cytokines (TNF, interleukins and interferons) 
and acute phase reactants, such as CRP. Inflammatory cytokines are thus paramount 
to the pathophysiology of cancer-associated thrombosis.137  
TF is often expressed in response to tumor necrotizing factor (TNF), interleukins (IL-
1, IL-2 and IL-6), interferons and plasmin. Also monocytes and endothelial cells can 
become procoagulant under the influence of cancer-mediated cytokine release.138 
TNF can also suppress the fibrinolytic activity of the endothelium, meanwhile 
cytokines in general can also cause inflammation of the endothelial lining creating a 
prothrombotic surface, triggering thromboembolic events.139 
Another immune response that affects cancer-associated thrombosis and coagulation 
is that of neutrophil extracellular traps (NETs).140 NETs are components of the innate 
immune system, produced by neutrophils to trap microbes. Tumor cells can stimulate 
neutrophils to release NETs,141 where they in turn will cause platelet aggregation and 
activation of other coagulation factors.142 NETs were only first discovered in 2004, 
but will remain important as they now have been shown in ischemic stroke 
thrombi.143 
Worthy of note is the fact that IL promote procoagulant secretion from endothelial 
cells, and the endothelial cells will in turn respond to this stimulus by secreting IL, 
thus creating continuous stimuli for inducing an inflammatory response. This is seen 
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throughout the studies on cancer-thrombosis pathophysiology; indefinite circuits of 
prothrombotic stimuli are created.138 
This is also the instance for selectins; cell adhesion molecules. Selectins are normally 
expressed by healthy cells, but they are expressed at a higher rate under tumor cell 
stimulation. Selectins will in turn increase TF-expression on endothelial cells and 
monocytes.144 Selectins on tumor cell surfaces can moreover cause platelet activation 
and aggregation. As such, it has been hypothesized that an increase in selectins is 
associated with risk of thromboembolic events in cancer patients.145 Also endothelial 
cells can be stimulated to produce “platelet activating factor”.  
We do not yet fully understand the intricate factors of hypercoagulation, nor do we 
know which factors are the most important. The induction of hypercoagulability 
probably also differs from tumor cell type, to cancer stage and other innate factors.146 
Though, in summary, what has been recognized, is that hypercoagulation is mediated 
by 1) prothrombotic factors from tumor cells; solid or CTCs, 2) prothrombotic factors 
from healthy cells after tumor cell stimuli, 3) decreased level of inhibitors of 
coagulation and/or 4) through a systemic inflammatory response to tumor cells.  
Lastly, it should be mentioned that tumor-secreted and induced procoagulant factors 
are also promoters of tumor metastasis and tumor angiogenesis.132 
 
Hypercoagulability - clinically  
Although many of the coagulation factors are difficult to measure, there are two that 
can be used as signs of activated coagulation: elevated D-dimer and fibrinogen. 
Fibrinogen is an acute phase reactant, and therefore increases in response to 
inflammation. Elevated fibrinogen has been linked to an increased risk of thrombotic 
disease,147 and is studied in the patients included in studies I-III.  
D-dimer is a fibrin degradation product (FDP), a small protein fragment present in the 
blood after a blood clot has been broken down through fibrinolysis; the body‘s own 
clot-dissolving mechanisms. It is named D-dimer because it contains two cross-linked 
D-fragments of the fibrin protein. In a healthy person D-dimer is normally not present 
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in the blood, therefore D-dimer presence suggests the presence of clot-formation or 
thrombosis. Since it often used as a sign of hypercoagulability, D-dimer 
measurements were vital in the included studies. 
TF, CP and CTCs have been suggested as biomarkers for both cancer activity and 















Deciphering the risk of a cancer-associated stroke 
Cancer is in itself an independent risk factor for ischemic stroke.151 The risk can be 
potentiated by other, classical cardiovascular risk factors, but not necessarily.106  
For a cancer patient, the risk of ischemic stroke is reportedly higher shortly after 
diagnosis.106 A large-scale study from Sweden showed that risk of stroke post cancer 
is the highest in the first six months, however, the risk remains increased for a 
decade.152 127, 144 Increased stroke risk is also seen in cancer patients with 
metastasis.152 Historically, mucin-producing adenocarcinomas were found to be the 
strongest inducers of cancer-associated hypercoagulability and thus 
thromboembolism.139, 144, 153 This is still consistent with studies showing that the 
cancer types most commonly associated with stroke are lung cancer, colorectal 
cancer, breast cancer, pancreatic cancer, gynaecological cancer and gastric cancer; 
often adenocarcinomas.110, 117, 154, 155 However, today there are theories on non-mucin 
producing tumours also inducing hypercoagulable states. Supporting this belief is the 
fact that no study has been able to prove the procoagulant activity of, or procoagulant 
factor in, mucin.127  
 
Stroke and cancer epidemiology 
A global perspective 
Stroke and cancer are both leading causes of death in the Western world. Stroke alone 
is the leading cause of disability globally.156 CVD, including stroke, is one of the 
main types of the “non-communicable diseases” (NCDs), in addition to cancer, DM 
and chronic respiratory disorders. NCDs are induced and affected by both modifiable 
and non-modifiable risk factors.157 
Figure 3, panel A, shows that stroke and cancer are the leading causes of death 
globally, studying NCDs, and that this has increased in the last decades.158 Figure 3, 
panel B, shows that stroke and cancer are responsible for the highest number of 
Disease Adjusted Life Years (DALYs) lost globally. 
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Figure 3. Non-Communicable Diseases and Global Deaths.  
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Adapted from Hunter et al., NEJM, 2013. 158 
 
To measure the global burden of specific diseases, the Global Burden of Disease 
(GBD) study was launched in 1991 by the WHO and the World Bank. The GBD 
study integrates data on prevalence, incidence, and mortality to portray the true global 
cardiovascular burden. The most recent results from the “GBD 2015” showed once 
more that CVD is responsible for major loss of health globally.159  
There are great disparities in ischemic stroke incidence, mortality and burden 
between high-income countries and the low- and middle-income countries (LMIC).156  
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According to the WHO, approximately 80% of all CVD occurs in LMIC.53 Stroke 
incidence has decreased in high-income countries. The same countries have also seen 
a reduction in stroke mortality due to better treatment.160 
However, total stroke incidence has increased globally in the last two decades; 
especially in LMIC has the incidence of first-ever ischemic stroke increased 
significantly (Figure 4, panels A-C).161  
The NCD burden is one of the biggest health threats of this century, with the potential 
to increase health inequalities globally.65 Therefore it became a goal of the American 
Heart Association/ American Stroke Association to lower CVD morbidity and 
mortality by 20 % from 2010 to year 2020.162 
 
Economic burden 
Based on today’s numbers, predictions for the next couple of decades show that the 
stroke incidence will increase by 50 % in our ageing population.163 This will certainly 
have a global economic impact. A study instigated by the World Economic Forum 
estimated that the cost of all NCDs over the next 20 years could total 47 trillion 
United States Dollars (USD). The rise of NCDs in LMIC is worrisome, as the 
increase can greatly affect a country’s gross domestic product (GDP) as they often 
are costly to treat, and often disables the patients permanently. The loss of labor in 
the most productive years of life can in turn cause great loss of capital.  
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Figure 4. Incidence of first-ever ischemic stroke per 100.000 person-years for the 
years A: 1990, B:  2005, and C: 2010. 
 
Adapted from Krishnamurthi et al., The lancet , 2013 164  
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Stroke in Norway 
Estimates of stroke incidence in Norway are sparse, and vary depending on 
geographic location and the form of data registration.165-167  
Gaging the true stroke incidence has been difficult for many reasons. Firstly, stroke 
diagnosis and treatment is handled differently depending on the proximity to a stroke 
center. Secondly, certain stroke patients will suffer a stroke while in a healthcare 
facility, for instance in end-of-life-care or in palliative care, where a capable 
physician will know that treatment or further stroke diagnostics are not warranted. 
Also, there are some patients in nursing homes with recurrent stroke where, again, 
diagnosis will not implicate treatment, and they are therefore not transferred to a 
stroke center. This means that not every stroke diagnosis has been registered through 
the hospitals’ International Coding of Diseases (ICD-10) system.  
However, the accuracy of the monitoring of stroke diagnoses and stroke care is 
improving as Norway now has a national stroke registry with mandatory inclusion.168 
Latest consensus is that each year approximately 12.000 Norwegians suffer an acute 
stroke.169 These figures include all types of stroke, and recent reports show that 
ischemic stroke still constitutes about 85 % of all strokes.166  
Haukeland University Hospital, home of NORSTROKE, is the biggest hospital of the 
Western Norway Regional Health Authority and serves a well-defined area of 
approximately 250.000 inhabitants (Figure 5). It also serves as one of the two of the 
region’s EVT centra. Here, the incidence of ischemic stroke has been shown to be 
105 per 100,000 citizens per year.170 
The annual costs associated with acute strokes are in Norway about 8 billion 
Norwegian Kroner (NOK).171 A stroke victim may suffer permanent neurological 
deficits and need increased or full-time care at great expense of the public health care 
system. Of the patients that survive their stroke, around 50 % of them will have some 
form of permanent neurological deficit, many of them requiring long-term 
rehabilitation or care services for activities of daily living (ADL).172 
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The cancer-stroke connection in Norway 
The cancer-stroke connection has not been studied in Norway previously. Worldwide, 
stroke and cancer are leading causes of death, which is also true in Norway. 
According to the Norwegian Cause of Death Registry and the Norwegian 
Cardiovascular Disease Registry, cancer has now surpassed CVD as the leading cause 
of death in all age groups below 80 years. Cardiovascular disease is the most 
common cause of mortality in those above 80 years.174  
Due to public health improvements, such as a reduction in tobacco use and less 
hypertension, the overall incidence of stroke and cardiovascular disease is 
declining.174 However, the post-war generation is ageing, there is general population 
growth and other risk factors such as obesity are on the incline. Furthermore, a higher 
number of patients survive their cancer, stroke and heart attack, as treatment options 
are increased and improved. Consequently the prevalence of both stroke and cancer is 
rising. As such, cancer-associated strokes will also become more prevalent. 16,57  
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Further knowledge on what subgroups of patients are at highest risk for both stroke 
and cancer is needed. This could lead to implementation of new treatment options or 
lead to specific diagnostic investigations in patient groups at risk for cancer-
associated stroke. We know that cancer patients who suffer a stroke have poorer 
outcomes,175 and both diseases are associated with large economic burdens for 
society. Therefore, preventing a stroke in a cancer patient or detecting an occult 
cancer in a stroke patient is beneficial. 
 
Note 
The review of literature for the present thesis was completed within February 2018. 
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Aims of the thesis 
The primary aim of the study was to investigate the associations between cancer and 
ischemic stroke within the NORSTROKE registry. Three studies provide 
investigation into the associations within distinct study populations. 
 
1. To assess the prevalence of cancer in ischemic stroke patients compared to the 
general population. To assess what cancer types are the most common in 
stroke patients and what are their stroke etiologies as well as risk factors. This 
is discussed in paper I.  
 
2. To assess the frequency of cancer in patients who had recently suffered 
ischemic strokes and to investigate whether certain strokes should be classified 
as “cancer-associated” due to underlying malignancy at the time of ictus. To 
assess whether undetermined stroke etiology predicts underlying malignancy, 
and whether routine screening for cancer is warranted in every patient with 
ischemic stroke. This is discussed in paper II. 
 
3. To assess how to detect active cancer in ischemic stroke patients and best 
decide which stroke patients to screen for occult cancer. This is discussed in 
paper III. 
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The Bergen NORSTROKE Study 
Data for the present thesis was obtained from The Bergen NORSTROKE Study. The 
Bergen NORSTROKE Study prospectively registers all patients admitted to the 
Stroke Unit at Haukeland University Hospital diagnosed with IS, ICH and TIA. 
Haukeland University Hospital serves an area of about 250.000 inhabitants and has a 
comprehensive Stroke Center that, as one of five centers in Norway, provides state-
of-the-art endovascular stroke treatment.  
Data collection for the Norwegian Stroke Research Registry (NORSTROKE) was 
commenced in February of 2006 and will continue indefinitely. Data registration 
comprises a standardized form, which today is integrated in the routines in the Stroke 
Unit and prospectively filled out during treatment and follow-up.  
NORSTROKE includes all key patient data; demographics, medical history, clinical 
findings and vital parameters during hospital stay, blood samples, radiological 
findings, treatment prior to – and during admission, and finally short-term outcome. 
Medications used prior to admission are also registered. 
 
Risk factor definitions 
Risk factors are registered in NORSTROKE upon admission. They are defined 
according to current protocol in the Stroke Unit and include hypertension (HT), 
diabetes mellitus (DM), paroxysmal or chronic atrial fibrillation (AF), prior stroke, 
transitory ischemic attack (TIA), angina pectoris (AP), coronary artery disease 
(CAD), myocardial infarction (MI), peripheral artery disease (PAD), hyperlipidemia 
(HL), intermittent claudication and smoking. 
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DM was defined by diagnosis or treatment with any glucose lowering - medication or 
diet prior to hospital admission, or if revealed on admission for index stroke  
(HbA1c > 6.4%).176, 177 HT was also defined as diagnosis or treatment prior to 
hospital admission. AF was defined as paroxysmal or chronic AF confirmed by 
electrocardiogram (ECG) before the stroke. Smoking was categorized as active 
smokers (if smoking at least 1 cigarette per day), previous smokers (if quitting 
smoking at least 1 year prior to index stroke) and never smoker.  
 
Stroke diagnostics and imaging 
All stroke patients underwent urgent cerebral CT (computed tomography) on 
admission. Patients admitted within 6 hours of ictus also underwent CT angiography 
(CTA), which was performed using an IV contrast medium to visualize the arterial 
tree; both the neck- and the intracranial vessels. This enabled assessment of possible 
occlusions and to ascertain whether EVT would be feasible. In addition, CTA 
represents a mean to radiologically determine the severity of the stroke in the acute 
phase, as large vessel occlusion seen on CTA has a worse prognosis than small vessel 
occlusion.178, 179 
Cerebral CT was repeated throughout the acute phase if indicated by clinical 
worsening of the stroke patient; noticed either by an increase in the NIHSS score or 
reductions of the GCS score.  
Routinely, all stroke patients underwent magnetic resonance imaging (MRI) within 
the first day post stroke ictus, unless contraindicated. All MRI investigations were 
performed using 1.5 Tesla Siemens Magnetom (Symphony). A Diffusion Weighted 
Imaging (DWI)-sequence was performed as part of the stroke patient MRI protocol. 
The DWI-sequence used was ep2d_diff_3scan_trace, with the following 
specifications of parameters: field of view (FOV) 230 mm, slice thickness 5 mm, TR 
3200 ms, TE 94 ms. Additional sequences were t2_flair_tra and 
ep2e_diff_3scan_trace_ADC. All MRI scans were reviewed by a neuro-radiologist as 
well as by a stroke neurologist (HN).180 “Multiple acute cerebral infarcts” (MACI) on 
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DWI was defined as having lesion(s) in a minimum of two different arterial territories 
(right or left anterior or posterior cerebral circulation).181 This equaled involvement of 
1) bilateral anterior circulation, 2) unilateral anterior and posterior circulation or 3) 
bilateral anterior and posterior circulation. The anterior vascular territory included the 
anterior cerebral artery (ACA), the middle cerebral artery (MCA), the leptomeningeal 
branches of the MCA and ACA, the anterior choroidal artery (AchA) as well as the 
perforating branches of ACA, MCA and AchA. The posterior vascular territory 
included the vertebral artery, the basilar artery, the superior cerebellar artery, the 
posterior inferior cerebellar artery, the anterior inferior cerebellar artery and the 
posterior cerebral artery as well as perforating branches.182  
ECG was obtained in all patients and Holter monitoring was done in selected patients 
with embolic stroke of unknown etiology. Trans-esophageal or trans-thoracic 
echocardiogram was performed in the Cardiology Ward if indicated. Duplex-
sonography and color-coded sonography of the carotid arteries was performed in all 
stroke patients. The sonography was performed by a resident or attending neurologist 
from the Stroke Unit.  
 
Cancer data & The Cancer Registry of Norway 
All new cancer diagnoses are to be registered in the Cancer Registry of Norway by 
the treating physician. Any physician is obliged to register cancer diagnoses within a 
specific time frame, and this has been common practice since 1951. Due to 
Norwegian personal identification numbers, a public health care system and the 
mandatory registering, the Cancer Registry is one of the oldest and most 
comprehensive cancer registries globally. It is estimated that it contains at least 
98.8% of all cancer diagnoses in Norway.183 
The present study used data from the Cancer Registry through linking the personal 
identification numbers from NORSTROKE with the Cancer Registry. This enabled 
quality assurance of the cancer data registered in NORSTROKE.  
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There were 42 separate cancer diagnoses identified in the Cancer Registry that were 
not registered in NORSTROKE.  
Extracting and matching data in this manner was a careful process, completed in 
2012. The Cancer Registry informs that the interpretation and reporting of these data 
are the complete responsibility of the researcher. Endorsement by the Cancer Registry 
of Norway was not intended and should not be inferred. 
For the studies included in the present thesis, date of cancer diagnosis was set as the 
date of the pathology report stating a cancer diagnosis. If missing, the diagnosis date 
used was the date of the first hospitalization for cancer treatment. In the final paper, 
active cancer was studied. Active cancer was defined as 1) new cancer diagnosis,  
2) metastasis of known cancer, 3) recurrent cancer or 4) receiving cancer treatment, 
all within 12 months before or after the index stroke. 
 
Stroke etiology 
To assess the cause of the ischemic stroke, the stroke etiology, criteria from the Trial 
of Org 10172 in Acute Stroke Treatment (TOAST) were used.184 Inter-observer 
agreement has been found satisfactory.185  
The etiology by use of TOAST criteria was classified as follows:184 
 Large-artery atherosclerosis (embolus/ thrombosis) 
 Cardioembolism (high-risk / medium-risk)* 
 Small-vessel occlusion (lacune) 
 Stroke of other etiology (i.e. cancer or dissection)  
 Stroke of undetermined etiology (i.e. competing etiologies or cryptogenic 
stroke) 
- Two or more causes identified 
- Negative evaluation 
- Incomplete evaluation 
* Possible or probable depending on results from other examinations 
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The treating physician and/or a senior stroke physician in the Stroke Unit, determine 
the stroke etiology based on results from a series of routine investigations. In the 
present studies, all stroke etiologies were determined by neurologist and stroke 
specialist Professor Halvor Næss. As indicated in the TOAST overview, a stroke may 
have more than one probable etiology and still be classified as stroke of undetermined 
etiology. 
A large-scale study of European stroke patients estimated that about 30% of ischemic 
stroke patients have cardioembolic etiology, 15% large-artery atherosclerosis, 25% 
small-vessel occlusion and 20% other determined etiology.186 The etiological 
distribution does vary somewhat between different reports and study populations.185, 
187-189 Consensus is that about 40% of all ischemic stroke patients are classified with 
undetermined etiology.184, 188 This is similar to the etiological distribution in the 
NORSTROKE registry patients. The number of stroke patients with undetermined 
etiology remains quite high, but also includes patients with two or more potential 
causes that are equally likely to have caused the stroke. 
 
Stroke severity and the National Institutes of Health Stroke Scale  
To determine stroke severity, the National Institutes of Health Stroke Scale (NIHSS) 
was used. This is the standard tool for quantifying neurological deficits and stroke 
severity. It has also become important in acute stroke treatment as it is often used as 
an aid to determine which patients get thrombolytic treatment and which do not; no 
findings on the NIHSS, a score of zero, equals no IV tPA in many cases. As such it 
functions as the primary selection method in acute stroke. Although it was first 
intended for use solely in clinical trials of stroke patients,190 it is today an integral part 
of stroke treatment, observation and outcome prediction.191  
The score ranges from 0 - 42, where a score of 42 is the most severe and 0 is no 
functional or clinical neurological deficits.192 The stroke patient is scored with NIHSS 
immediately upon arrival to the hospital, after 1 hour and subsequently at 
standardized intervals by a stroke nurse in the Stroke Unit to monitor improvement, 
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stability or progression. This serial assessment with the NIHSS score also helps 
clinicians to catch early deterioration after thrombolytic treatment; most importantly 
stroke in progression, for example caused by progressing occlusion of an artery or its 
collaterals, increasing intracranial edema or intracerebral haemorrhage. 
It has been noted that the NIHSS score is biased in its sensitivity towards symptoms 
from the anterior circulation,193 and that it is heavily weighted towards detecting 
weakened motor function, as opposed to cognitive impairment.194 The NIHSS score 
does not, for instance, pick up apraxia or a loss of fine motor skills, which can both 
be debilitating for the affected patient.  
Another weakness of the NIHSS score is that it predicts arterial occlusion more 
accurately if the stroke patient is assessed shortly after debut of symptoms.195 
Nevertheless, the NIHSS score used globally and its validity has been deemed more 
than satisfactory, both in the acute phase and the serial assessment.196 It has even 
been shown that the NIHSS score can be predicted quite accurately retrospectively 
based on clinical findings.197  
 
Short-term functional outcome and the modified Rankin Scale 
On day 7 or on the day of discharge from the Stroke Unit, the short-term functional 
outcome of the stroke patient is determined by use of the modified Rankin Scale 
(mRS). This score is a valid method commonly used in stroke units to determine the 
stroke patients’ disability or dependence and the functional outcome.198 The score 
ranges from 0-6, where 0 is no symptoms at all, and 6 is dead. Score 0-2 indicates 
that the patient is independent, while score 5 indicates need for fulltime care. 






Paper I studied cancer prior to ischemic stroke. Between February 2006 and August 
2011, 1511 ischemic stroke patients were submitted to NORSTROKE. The study in 
Paper I included all patients with ischemic stroke in NORSTROKE who were not 
diagnosed with cancer post index stroke, as these 55 patients were excluded from the 
study. Of the 1456 patients included, 229 (15.7%) had one or more cancer diagnoses 
prior to their index stroke. In this study, cancer prevalence in our study population 
was compared to that of the general population of Norway. For this purpose, 
prevalence rates from the NORDCAN database, which provides cancer statistics for 
all the Nordic countries, was used.199 
  
Commonest cancer types: 
Colorectal, N = 55 
Prostate, N = 42 
Breast, N = 31 
Urinary syst., N = 28 
Gynecological, N = 16 
Lung, N = 12 
Ischemic Stroke Patients in NORSTROKE  
Admitted Feb. 2006 - Aug. 2011.  
N = 1511 
Cancer prior to stroke 
 N = 229 
No history of cancer 
 N = 1227 
Excluded: Cancer 
post stroke 
 N = 55 
Included patients 
N = 1456 
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Paper II studied cancer diagnosed post stroke in the patients from the same inclusion 
period as study I (February 2006- August 2011). However, in this study, patients with 
cancer prior to stroke were excluded. After excluding patients with a history of 
cancer, 1282 ischemic stroke patients were included. Of these, 55 patients were 
diagnosed with cancer after their stroke within the study’s end-point; September 15th, 
2011 or date of death if prior to study end-point. The 55 patients were diagnosed with 
a total of 64 diagnoses, of 13 different cancer types. Twenty-three of the patients 
were diagnosed with cancer within one year post stroke, while median time from 
stroke to cancer diagnosis was 14 months. The follow-up time, however, varied 
between patients, and therefore, some patients only had a three week window to be 




















Ischemic Stroke Patients in NORSTROKE  
Admitted Feb. 2006 - Aug. 2011.  
N = 1511 
No history of cancer 
 N = 1227 
Cancer post stroke 
 N = 55 
Commonest cancer types: 
Lung, N = 12 
Prostate, N = 10 
Colorectal, N = 7 
Breast, N = 7 
Gynecological, N = 5 
CUP,* N = 4 
Lymphoma, N = 4 
 




 N = 229 
Included patients 
N = 1282 
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Paper III studied how to predict if an ischemic stroke patient had active cancer. This 
study had a longer follow-up time of the patients than paper I-II. Patients were 
included from February 2006 until January 2012, and follow-up was through August 
2012. After excluding 250 patients with inactive cancer, 1646 patients were included, 
and of these, 82 had active cancer as defined on page 45 of the present thesis. In this 
study, the data from patients with active cancer and ischemic stroke was compiled 
and analysed to form a predictive score for clinical use. The aim of the score was to 
be a tool for deciding which ischemic stroke patients should be screened for cancer.  
  
Ischemic Stroke Patients in NORSTROKE  
Admitted Feb. 2006 - Jan. 2012.  
N = 1896 
Active cancer types: 
Prostate, N = 18 
Lung, N = 17 
Colorectal, N = 13 
Bladder, N = 10 
Gynecological, N = 4 
Pancreas, N = 3 
Gastric, N = 3 
Malignant melanoma, N = 3 
 
No history of cancer 
 N = 1564 
Active cancer 
 N = 82 
Excluded: 
Inactive cancer 
 N = 250 
Included patients 
N = 1646 
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Statistics 
Two-sample Student’s t-test was used for continuous variables with a normal 
distribution, while Mann-Whitney U test was used for the variables not normally 
distributed. Chi-square analysis was used for categorical variables. Cox regression 
analysis was used to investigate survival. The study populations were dichotomized 
as ischemic stroke patients with active- , prior - or post-stroke- cancer and stroke 
patients with no history of cancer (never cancer), with never cancer serving as the 
control group. Logistic regression analysis with the cancer group versus never cancer 
as the dependent factor was used to determine variables independently associated 
with active cancer, prior cancer or cancer post stroke. Regression analyses were 
performed stepwise by backward elimination.  
For paper III, variables independently associated with active cancer were chosen as 
clinical markers and dichotomized. The clinical markers were based on cut-off levels 
and entered in a clinical score. Different scores were compared using the area under 
the receiver operating characteristic (AUC-ROC) curves. Area Under the Curve 
(AUC) determined the strength of the score; 0.7- 0.8 was considered a fair AUC. 200 
Bayes’ theorem was used to calculate post-test probabilities of active cancer in paper 
III. All p-values of < 0.05 were considered statistically significant. Analyses were 
executed using statistical software Stata 14.0 (Stata Corp College Station, TX). 
 
Ethical considerations 
The NORSTROKE registry is based upon written consent and informed consent was 
obtained from all patients or legal guardians included in the studies.  
The study of cancer-associated stroke by use of NORSTROKE data was approved by 
the Regional Committee for medical and health research ethics (REK Vest) in 2012. 
All data in possession of the author from the Cancer Registry of Norway was deleted 
by December 31st, 2017 as per the written agreement. This was to ensure that cancer 
data cannot be used for other than the studies’ intended purposes.  
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Summary of the included papers 
Paper I:  
Prior Cancer in Patients with Ischemic Stroke: The Bergen NORSTROKE 
Study. Selvik HA, Thomassen L, Logallo N, Naess H. J Stroke Cerebrovasc Dis 
2014 May-Jun; 23(5):919-25 
Background: It has been shown that ischemic stroke occurs more frequently in 
cancer patients than in the general population. The aim of this study was to compare 
the prevalence of prior or on-going cancer in patients with ischemic stroke and in the 
general population. We hypothesized that cardioembolic stroke is the most common 
stroke etiology in patients with prior cancer and that the outcome for ischemic stroke 
patients (ISP) with prior cancer is poor. 
Methods: All ISP registered in the Norwegian Stroke Research Registry 
(NORSTROKE) as part of the ongoing Bergen NORSTROKE Study were included. 
Stroke etiology was determined by the Trial of Org 10172 in Acute Stroke Treatment 
criteria, and the severity of the stroke was defined from the National Institutes of 
Health Stroke Scale score. Information about prior or ongoing cancer disease and 
type was retrospectively obtained from the medical patient record and The Cancer 
Registry of Norway. The prevalence of cancer among stroke patients was compared 
with the prevalence of cancer in the general population. 
Results: Among 1456 ISP, 229 (15.7%) patients had 1 or more cancer diagnoses 
before the stroke. The prevalence of cancer was higher among stroke patients 
compared with the general population (P = .001). The most common cancer types 
were colorectal cancer (20.2%), prostate cancer (15.6%), breast cancer (12.7 %), 
cancer of the urinary tract system (10.3%), gynecological cancer (6.2%), and lung 
cancer (4.5%). Logistic regression analysis showed that patients with prior cancer had 
cardioembolic strokes at a higher rate (P = .03). 
Conclusions: The prevalence of prior cancer is higher in ISP than in the general 
population. ISPs with prior cancer are more prone to cardioembolism.  
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Paper II:  
Cancer-Associated Stroke: The Bergen NORSTROKE Study. Selvik HA, 
Thomassen L, Bjerkreim AT, Naess H. Cerebrovasc Dis Extra 2015 Oct 13; 
5(3):107-13 
Background: Underlying malignancy can cause ischemic stroke in some patients. 
Mechanisms include the affection of the coagulation cascade, tumor mucin secretion, 
infections and nonbacterial endocarditis. The release of necrotizing factor and 
interleukins may cause inflammation of the endothelial lining, creating a 
prothrombotic surface that triggers thromboembolic events, including stroke. The 
aims of this study were to assess the occurrence of cancer in patients who had 
recently suffered an ischemic stroke and to detect possible associations between 
stroke and cancer subtypes. 
Methods: All ischemic stroke patients registered in the Norwegian Stroke Research 
Registry (NORSTROKE) as part of the ongoing Bergen NORSTROKE study were 
included. Patients with a history of cancer were excluded from the study. Blood 
samples were obtained on admission. Stroke etiology was determined by the Trial of 
Org 10172 in Acute Stroke Treatment (TOAST) criteria, and the severity of stroke 
was defined according to the National Institute of Health Stroke Scale score. 
Information about cancer disease after stroke was obtained from patient medical 
records and The Cancer Registry of Norway. 
Results: From a total of 1,282 ischemic stroke patients with no history of cancer, 55 
(4.3%) patients were diagnosed with cancer after stroke. The 55 patients were 
diagnosed with a total of 64 cancer diagnoses; of 13 different cancer types. The 
median time from stroke onset to cancer diagnosis was 14.0 months (interquartile 
range 6.2-24.5). Twenty-three (41.8%) patients were diagnosed with cancer within 1 
year and 13 (23.6%) within 6 months. The most common cancer type was lung cancer 
(19.0%). By Cox regression analysis, cancer after stroke was associated with elevated 
D-dimer levels on admittance (p < 0.001), age (p = 0.01) and smoking (p = 0.04). 
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Conclusions: Cancer-associated stroke is rare, and routine investigation for cancer 
seems unwarranted in acute ischemic stroke. However, in stroke patients with 
elevated levels of blood coagulation factors, C-reactive protein, higher age and a 
history of smoking, underlying malignancy should be considered. Our study suggests 




When to Screen Ischaemic Stroke Patients for Cancer. Selvik HA, Bjerkreim 
AT, Thomassen L, Waje-Andreassen U, Naess H, Kvistad C.E. Cerebrovasc Dis. 
2018 Jan 9;45(1-2):42-47 
Background: Ischemic stroke can be the first manifestation of cancer and it is 
therefore important to ascertain which stroke patients should be considered for 
cancer-diagnostic investigations. We aimed to determine the frequency of active 
cancer in patients with acute ischemic stroke and to compare clinical findings in 
stroke patients with active cancer to ischemic stroke patients with no history of 
cancer. Finally, we aimed to develop a predictive and feasible score for clinical use to 
uncover underlying malignancy. 
Methods: All ischemic stroke patients admitted to the stroke unit in the Department 
of Neurology, Haukeland University Hospital were consecutively included in the 
Norwegian Stroke Research Registry (NORSTROKE). Stroke etiology was 
determined by the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. 
Data on cancer diagnoses was obtained from patients' medical records and 
the Cancer Registry of Norway. Active cancer was defined as cancer diagnosis, 
metastasis of known cancer, recurrent cancer or receiving cancer treatment, all within 
12 months before or after the index stroke. Based on variables independently 
associated with active cancer, a predictive score was developed using the area under 
the receiver operating characteristic (AUC-ROC) curves. Bayes' theorem was used to 
calculate post-test probabilities of active cancer. 
Results: Of the 1,646 ischemic stroke patients included, 82 (5.0%) had active cancer. 
Increased D-dimer (OR = 1.1, 95% CI: 1.1-1.2, p = <0.001), lower Hb (OR = 0.6, 
95% CI: 0.5-0.7, p = <0.001), smoking (OR = 2.2, 95% CI: 1.2-4.3, p = 0.02) and 
suffering a stroke of undetermined etiology (OR = 1.9, 95% CI: 1.1-3.3, p = 0.03) 
were factors independently associated with active cancer. These were included in the 
final predictive score which gave an AUC of 0.73 (95% CI: 0.65-0.81) in patients 
younger than 75 years of age. Assuming the prevalence of cancer to be 5%, the score 
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shows that if a patient fulfills all 3 score points, the probability of active cancer is 
53%. 
Conclusions: Active cancer was found in 5% of our ischemic stroke patients. We 
found that a clinical score comprising elevated D-dimer ≥3 mg/L, lower Hb ≤12.0 
g/dL and previous or current smoking is feasible for predicting active cancer in 
ischemic stroke patients.  
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General Discussion 
Age and other risk factors 
Age matters  
In Norway, about 70 % of all strokes take place in persons above the age of 75 
years.167 The age demographics of our study populations were quite similar to what 
one would expect of a stroke population, but it differed between stroke patients with 
and without cancer. In paper I, the mean age was higher in patients with cancer prior 
to their stroke than in patients with no history of cancer (76.1 years versus 69.5 
years). In the same study we found that the cancer prevalence was significantly 
higher in our NORSTROKE population than the general population of Western 
Norway, for all persons below 70 years. This finding suggests that cancer is an 
independent risk factor for ischemic stroke or associated with common risk factors 
for both stroke and cancer. In this study we also analyzed each cancer type separately, 
comparing the patients with the 7 most common cancer types to patients with no 
history of cancer. The age of the lung cancer group stood out as they were much 
younger than the other groups as well as the control group with no cancer, with their 
mean age of 67.2 years.  
In paper II patients with cancer after stroke also had a higher mean age than patients 
with no history of cancer, 72.7 years versus 69.5 years, but this was not statistically 
significant. 
In paper III, a score was developed to screen stroke patients for active cancer. Again, 
patients with active cancer were older than stroke patients with no history of cancer; 
73.7 years versus 69.5 years. The score included blood levels of hemoglobin (Hb) and 
D-dimer on admission, as well as smoking habits. Using AUC to assess the best 
score, the final score was only feasible for patients below 75 years of age. In patients 
above 75 years the sensitivity was too low, indicating that Hb and D-dimer were not 
viable markers for differentiating between a stroke patient with and without active 
cancer at this age. Anemia, defined by WHO as Hb < 13 g/dL and < 12 g/dL for men 
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and women respectively, is more common in the elderly.201  
After the age of 65, around 5 - 10 % of the general population has anemia, and the 
prevalence increases with age.202 The prevalence in those above 85 years is reported 
at 20 %,203 and in populations with high comorbidity, such as inhabitants of nursing 
homes, even as high as 48 %.201 Certainly the anemia prevalence will vary depending 
on factors such as genetics and diet. However, even if the above mentioned 
prevalence of anemia is an overestimate, it provides an explanation for why anemia, 
specifically low Hb, becomes less discriminate with age and why the score is only 
feasible for those below 75 years.  
Similarly, the diagnostic value of D-dimer in the elderly has been discussed. As D-
dimer can increase with age, Righini et al. suggested using different cut-off values of 
D-dimer for predicting pulmonary embolism, especially in patients above 75 years.204  
Idiopathic increase in D-dimer in the elderly may diminish the specificity of D-dimer 
as a marker of coagulation.205 This is important to keep in mind as we used D-dimer 
as one of the point-giving factors in our predictive score. Nevertheless, we used D-
dimer above 3000 ng/mL as the cut-off value, a high value, outside the range of what 
is considered normal (Figure 6), even in elderly patients. 
 









Adapted from Tita-Nwa et al., Aging Clin Exp Res. 2010 205 
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Both cancer incidence and prevalence rise steeply with age. Age is the single most 
important risk factor for both stroke and cancer, and cogently the cancer prevalence 
increases with age, both in a stroke population as well as a general population.  
In papers I and II, prostate cancer was the second most common cancer type in the 
patients with stroke and cancer, and in paper III it was the most common cancer type. 
As prostate cancer is one of the least aggressive types of cancer, it is believed to less 
likely induce a hypercoagulable state and is thus only weakly associated with an 
increased risk of ischemic stroke.206 Its high prevalence in our studies might be due to 
its high incidence and prevalence in the general population.206 Furthermore, as the 
patients in paper I were significantly older, they had a higher risk of getting both 
stroke and cancer simply by living longer and ageing.  
 
 
Risk factors – conventional or distinctive? 
Risk factor distribution is a highly disputable topic when discussing cancer-associated 
stroke. The question remains: do patients with stroke and cancer have the same 
conventional stroke risk factors as stroke patients without cancer, or do they have 
distinctive risk factor patterns with fewer conventional stroke risk factors? 
When discussing risk factors for stroke, we think of the CVD risk factors such as age, 
HT, AF (chronic or paroxysmal), smoking, DM, PAD, known CVD and HL as well 
as others (see “Cardiovascular risk factors” in the Introduction).  
In papers I-III we found little discrepancy in CVD risk factor distribution between 
patients with and without cancer.  In paper I there was actually a higher frequency of 
patients with risk factors in the patients with cancer prior to stroke. Although these 
patients had a higher rate of hypertension and heart disease, this is probably a result 
of the patients being older and not indicative of a general increase in CVD risk 
factors for cancer patients. Smoking is the only risk factor that is distinctive in papers 
I-III. In paper I and II patients with stroke and cancer were more often smokers, and 
smoking is associated with long-term mortality for stroke patients with cancer pre – 
and post stroke. In paper III, smoking was independently associated with active 
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cancer as well as increased post-test probability of cancer by including smoking in 
the clinical score.  
Several studies have also reported a similar CVD risk factor profile in stroke patients 
with and without suspected cancer-related stroke.105, 109, 207-212 Others, such as 
Schwarzbach et al., have argued that stroke patients with cancer-related stroke have 
fewer conventional risk factors such as hypertension and hypercholesterolemia.103, 107, 
213  
Given the heterogeneity of cancer patients, perhaps this discussion has a scope that is 
too broad. Kim et al. studied the risk factor distribution on an etiological level. 
Instead of comparing patients with cancer-related stroke to other stroke patients, they 
compared patients with cancer-related stroke with different stroke etiologies, meaning 
they compared those of stroke of undetermined cause with the other etiologies.214 In 
doing this, Kim et al found that cancer patients with stroke of undetermined etiology 
had fewer conventional risk factors.  
The question of risk factors in cancer-related stroke might be moot. This is because 
the presence of conventional risk factors in stroke patients does not exclude the 
possibility of underlying cancer having contributed to the stroke. The reasoning for 
this is twofold. Firstly, a patient with for instance atherosclerosis from smoking can at 
random suffer both stroke and cancer. Secondly, a patient with atrial fibrillation and 
cancer can have an increased stroke risk from a hypercoagulable state, leading to 
stroke through amplification of the already present risk factor.   
Accepting the hypothesis that stroke patients with underlying cancer have fewer 
conventional risk factors could be harmful. In doing so, physicians could be led to 
wrongly categorize a patient a patient where conventional risk factors mask an 
underlying cancer’s involvement in stroke etiology. 
Finally, both stroke patients with no cancer and occult cancer can suffer strokes 
despite having no known risk factors. Analyzing our own database, NORSTROKE, 
19.3% of all ischemic stroke patients had no known traditional risk factors at the time 
of ictus.  
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Stroke etiology  
Should cancer-related stroke be its own etiology? 
Stroke etiology is also debated in relation to cancer-associated stroke.  
Several questions have been raised; what is the most common stroke etiology in 
cancer patients? Do they suffer strokes of all etiologies, or are they often cryptogenic 
strokes of undetermined etiology? Moreover, some have even suggested “cancer-
related stroke” as its own etiological classification.109 The most common viewpoint is 
that cancer-related stroke often remains of undetermined cause and that stroke 
patients with stroke of undetermined cause are more likely to have an underlying 
malignancy than other etiologies.213  
In paper I, we hypothesized that ischemic stroke patients with prior cancer had a 
higher rate of cardioembolic strokes. This was because a cancer-induced 
hypercoagulable state was believed to cause strokes of embolic cause and 
appearance.105 We found cardioembolic strokes of a higher rate in patients with prior 
cancer on logistic regression. Also, as this paper was a study of prevalence over a 
given time, we did not distinguish the patients according to time from cancer to ictus, 
which could have affected the findings.   
In paper II we studied stroke patients who were diagnosed with cancer post stroke, 
hypothesizing that some patients had underlying cancer at the time of stroke. Also in 
this population the stroke etiology was somewhat inconclusive. There was not one 
etiology that was significantly more common in patients with suspected cancer-
associated stroke. It would have been interesting to see which etiology the patients 
with the shortest time from stroke ictus to cancer diagnoses had. A recent study by 
Quintas et al. with identical study design to that in paper II, also showed a similar 
distribution of etiologies between patients diagnosed with cancer post stroke and 
patients with no history of cancer.212 They diagnosed approximately 3.4 % of their 
ischemic stroke patients with cancer within 6 months of stroke, yet, the distribution of 
etiologies was still the same; undetermined etiology was not more common in any 
cancer group than in patients with no history of cancer. 
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The inconclusive findings in paper II were part of what led us to the next study; only 
including patients with active cancer. In paper III with patients with active cancer, we 
found that undetermined etiology indeed predicted active cancer. Of the 82 patients 
with active cancer, 42 (50.6 %) had etiology of undetermined cause.  
In recent literature, the main focus on cancer-associated stroke is often on those of 
undetermined etiology.215 Not only have many studies concluded that undetermined 
cause is the most common in patients with stroke and cancer, but some have now 
even used etiology as a selection criteria for study participation, only including 
patients with undetermined etiology.216, 217  
However, as discussed in terms of how finding conventional risk factors does not 
exclude cancer, similarly, does known stroke etiology not exclude cancer.  
In fact, Aarnio et al., found that for stroke in the young, the cancer-associated strokes 
were especially not of undetermined cause.218 Aarnio’s young stroke patients with 
cancer had determined etiologies distributed similarly to the stroke patients with no 
cancer in the control group.218 Although it did not reach statistical significance, the 
young stroke patients had a higher rate or cardioembolic strokes, also after adjusting 
for patent foramen ovale (PFO).218 
Furthermore, Finelli et al. portrayed DWI-findings in patients with stroke and cancer, 
where 75 % of the patients with embolic appearing infarctions actually had emboli of 
no detected source.219 
Clinically, if patients have embolic appearing strokes and report symptoms that 
indicate a possible AF such as palpitations, even without ECG findings, they might 
be classified as cardioembolic. Thus, if one were to only include patients with 
undetermined etiology in the search for underlying cancer, one might lose patients in 
the classification.  
In our three studies we used the TOAST criteria to determine stroke etiology. The 
category of “stroke of undetermined etiology” includes both strokes of truly unknown 
cause, but also those with two or more possible etiologies, where either etiology is 
just as likely as the other. It would have been interesting to study the etiological 
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group of undetermined cause more in depth in papers I-III, dividing this etiological 
group in those of “no cause found” and “two or more possible” etiologies.  
Of the 42 patients with active cancer classified as “stroke of undetermined cause” in 
paper III, 5 also had AF, which could have been one contributing factor to their 




Determining the aftermath  
Functional outcome 
As described in the Methods section, the mRS was used to assess functional outcome 
after stroke; on day 7 or on discharge from hospital if sooner. It is known that patients 
with stroke and cancer have a poorer functional outcome after stroke compared to 
stroke patients in general.220 Even with acute stroke treatment, cancer patients with 
stroke fare poorly, with as many as 75 % of patients dependent on help or dead after 
three months.221 This is not surprising as both are serious diseases to be inflicted with. 
Cutting et al. showed that the stroke severity is the most important factor in 
determining the functional outcome; even more important than cancer type or 
stage.221 
In paper I we saw a poorer short-term outcome for patients with prior cancer as a 
group. Studying the separate groups of the most common cancer types, patients with 
prior colorectal- or lung cancer, had the poorest short-term outcome. Interestingly, 
these were also the two cancer groups that had a significantly higher NIHSS score on 
admission. 
In paper II we saw no significant mRS score differences in the patients diagnosed 
with cancer post stroke, neither when we assessed the separate cancer types. In this 
study, however, the cancer-group only included 55 patients.  
Also, in paper III, the active cancer patients had a poorer outcome than stroke patients 
with no history of cancer. Table 3 shows the mRS scores for the most common cancer 
types (paper I) or the patients with cancer (paper II and III) compared to the patients 
with no history of cancer. 
It is noteworthy that in the global stroke community, the mRS score is often the only 
outcome measure used, both in clinical practice and for research purposes. Within 
each mRS category there is room for a large variation of ADL management and thus 
quality of life. Although the mRS has been found reliable, it can overlook persistent 
problems such as light cognitive impairments or depression, important factors for 
quality of life. For example, a recent study by Kapoor et al. showed that among 
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patients who recovered from stroke and had an mRS score 0-1, more than half of the 
patients were cognitively impaired, and one third was depressed.222  
Given that Kapoor’s dire results were from a study of a general stroke population 
where stroke was the only diagnosis for many of his study subjects, it is certainly 
plausible that the findings would be similar or worse in a population of patients 
suffering from both stroke and cancer.  
Functional outcome as measured by mRS is important to measure post stroke. 
However, the pre-stroke mRS score may also be relevant in the acute phase. 
Discussing EVT, mRS 0-2 after thrombectomy is often considered a meaningful and 
satisfactory result or outcome. If a stroke patient is admitted with a pre-existing mRS 
of 4, this patient might not be considered for invasive treatment. It could be argued 
that premorbid mRS status should not be a considering factor however. For example, 
for the patient with a pre-stroke mRS score of 4, receiving EVT and thus remaining 
mRS 4, and not ending up with a post-stroke mRS score of 5, could pose huge 
potential for difference in quality of life. Another aspect of this is that the patients 
with a remaining mRS score of 4 would cost society significantly less by needing less 
assistance. Therefore it is arguably important that acute stroke treatment, including 
EVT, remains a top priority of funding and expansion in the years to come.  
 
Mortality 
Given the strong association between cancer-related stroke and poor clinical 
outcome, it is not surprising that the same patients also have an increased 
mortality.105, 218 
In paper I we found that stroke patients with prior cancer had a double risk of death 
compared to other stroke patients. In paper III we did not study the mortality of the 
patients, but we saw that the patients with active cancer had a lower mean cholesterol 
level. Because statin use is associated with lower cancer-related mortality,223 as well 
as stroke mortality224, it would have been interesting to study the overall medications 
used in our cancer population.  
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According to Cutting et al., 50 % of patients with stroke and cancer die within three 
months, regardless of cancer stage or type.221 Recent results from the OASIS-
CANCER Study in South Korea indicated that the degree of hypercoagulability is a 
factor in cancer-stroke mortality.225 This could possibly explain why the NIHSS score 




Table 3. mRS on day 7 or discharge for stroke patients with prior, post or active 
cancer compared to stroke patients with no history of cancer.   
 
  




Patients with prior cancer vs. patients with no history cancer 
 
Never cancer, n = 1227 2 (1-4) 
Colorectal, n = 55 3 (1-4)* 
Prostate, n = 42 2 (1-3) 
Breast, n = 31 3 (2-4) 
Urinary system, n = 28 2 (1-4) 
Gynecological cancer, n = 16 3 (1.5-4) 
Lung, n = 12 4 (2-4.5)* 
 
Paper II: 
Patients with cancer post stroke vs. patients with no history cancer 
 
Never cancer, n = 1227 2 (1-4) 
Cancer post stroke, n = 55 2 (1-4) 
 
Paper III: 
Patients with active cancer vs. patients with no history cancer 
 
Never cancer, n = 1564 2 (1-4) 
Active cancer, n = 82 2 (1-4) * 
 
 
mRS: modified Rankin Scale. IQR: Interquartile Range.  





Cancer prevalence  
In paper III, the prevalence of active cancer in NORSTROKE was 5 %.  
This was based on the follow-up time for all patients, where the active cancer 
diagnoses were registered during an interval of 12 months pre-stroke or 12 months 
post-stroke. This prevalence is not comparable to the cancer prevalence in a general 
stroke population, counting all cancer diagnoses. 
The prevalence of cancer in the general population of Norway was reported at 5.0 % 
in 2016 according to The Cancer Registry of Norway. The prevalence for the general 
population, however, includes all patients either living with active cancer or having 
survived a cancer diagnosis. Therefore, the prevalence of active cancer would likely 
be lower in the general population, as the prevalence of active cancer in 
NORSTROKE was based on the total 24-month interval pre and post stroke 
diagnosis, and thus did not include someone who had inactive cancer. 
Still, given the higher incidence of stroke in a cancer population, we would have 
expected that the active cancer prevalence was higher in an ischemic stroke 
population due to the shared risk factor burden. As recent reports have shown, 
patients with risk factors that increase both stroke and cancer risk may have a biology 
that predisposes them to both diseases.10 Therefore, one could have expected an 
increased active cancer prevalence in a stroke population.  
As seen in paper I, the prevalence of cancer is higher in the NORSTROKE 
population than in the general population of Western Norway in those below the age 
of 70. Last year, a comparable study from Germany also showed an increased cancer 
prevalence, especially of lung cancer, in their stroke population compared to the 
general population in Germany.226 
In our studies the most common cancer types were colorectal cancer, prostate cancer, 
lung cancer, breast cancer, cancer of the urinary system, gynecological cancer, 
lymphoma and cancer of unknown primary site. This is comparable to the most 
common cancer types in other studies.212 Still, these findings may reflect, and be 
affected by, the cancer prevalence in the general population. Thus do they not 
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necessarily reflect which cancers are the strongest inducers of hypercoagulability.  
As discussed by Lee et al. in one of the major studies on cancer and venous 
thromboembolic events, when adjusting for prevalence in the general population, the 
cancer types with the strongest effect on coagulation are lung cancer, cancer of 
unknown primary origin, pancreas cancer, brain cancer and ovarian cancer.121 Also 
gastric cancer, often adenocarcinoma, has been mentioned frequently in the literature 
as especially prothrombotic.227 
In our studies, there is a potential for underrepresentation of cancer-associated stroke 
prevalence. This is because not all stroke diagnoses are necessarily registered, as not 
all patients with stroke are hospitalized. In addition, even hospitalized cancer patients 
might suffer strokes that go untreated and thus unregistered. If a patient in palliative 
care suffers a stroke, this will likely be treated less acutely than if a healthy person 
suffers acute stroke, as other aspects may be more important in the end-of life phase. 
 
Defining active cancer 
In a study with an inclusion criteria of active cancer, such as paper III, the definition 
of active cancer will greatly impact the observed prevalence. We defined active 
cancer as 1) new cancer diagnosis, 2) metastasis of known cancer, 3) recurrent cancer 
or 4) receiving cancer treatment, all within 12 months before or after the index stroke. 
The more common way to define active cancer is the three points above, but all 
within 6 months before or after the index stroke. We performed preliminary analyses 
comparing the patients meeting the criteria for the 12-month definition to the patients 
in the 6-months definition. We found no significant differences between the groups 
and therefore chose to use the 12-month definition. 
A recent study by Guo et al. also used the 12-month definition,228 though the 6-month 
definition remains the one widely used.107, 229 Yet another definition used is active 
cancer within 12 months before index stroke or cancer diagnosis while in the stroke 
unit.230 
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This brings up another aspect of the active cancer definition. At what point does a 
cancer, solid or not, affect a patient negatively, and when could it affect coagulation? 
To answer this, one also has to answer the question of how long it takes for a cancer 
to proliferate. These are not easy questions to answer.  
A study of the time from first symptom to diagnosis of lung cancer in England 
showed that if a patient`s first symptom was worsening of a cough, or persistent 
cough > 3 weeks, median time to diagnosis was about 4.2 months.231 One can suspect 
that a cancer causing clinical symptoms has had an effect on the body’s homeostasis 
or coagulation for a weeks or months. As mentioned in paper III; a study of 
Trousseau syndrome showed that patients with idiopathic thromboembolic events had 
an increase in occult cancer prevalence from 6.1 % at the thromboembolic event to 
10.0 % at 12 months.232 This gives ample reason to believe that the occult cancer was 
present in the body, although not diagnosed, at time of event. This justifies including 





Cancer risk and screening 
Risk stratification and ROC curves 
In the 1950s, the idea of clinical prediction by use of a statistical method emerged. 
Much thanks to clinical psychologist Paul Meehl’s book “Clinical vs. Statistical 
Prediction: A Theoretical Analysis and a Review of the Evidence” published in 
1954,233 the ideal of the close to omnipotent doctor was questioned in terms of being 
the only one able to predict disease. Meehl suggested that algorithms and scores 
could be used to predict a patient’s combined risk of disease over time.  
In cardiovascular research especially, there has been a desire to stratify the risk of 
suffering acute events, such as stroke or heart attacks. In order to do so, scores to 
predict levels of risk at separate thresholds, as well as diagnostic tests, have been 
developed. The so-called C-statistic, or the Area Under the ROC Curve (AUC-ROC) 
is one of the frequently used statistics for prediction. The AUCROC will provide the 
researcher with a measurement of the accuracy of a score or diagnostic test.  
In paper III, we used AUCROC to develop a clinical score to predict active cancer in 
ischemic stroke patients. In a Circulation paper by Nancy Cook, a Harvard T. H. 
Chan School epidemiologist, the wide use of ROC curves was criticized.234 She 
argued that relying solely on the ROC curve is unwise because it does not portray the 
true risk.  
Certainly, no test or score can ever truly reflect the complex reality of nature and 
individual differences will always remain.  
As any diagnostic test, using a score from AUCROC is a function based on the 
sensitivity and specificity of each measure included in the model. This means that 
there inherently will be false negative, as well as false positive outcomes. The 
question is then how many false outcomes we are willing to endure in order to reveal 
the true outcomes, here active cancer. How do we screen for cancer in a way that 
maintains our ethical standard, costs, and the well-being of the patient?  
In paper III we constructed a score that may be used with caution in the clinical 
setting. In this study we argued that the score threshold of 2, with a 0.81 specificity 
and 13% post-test probability of cancer warranted screening. 
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Theories for cancer screening in ischemic stroke patients 
 
In paper II, we conclude that underlying occult cancer is too rare in ischemic stroke 
patients to warrant screening of all ischemic stroke patients. Others have also 
supported this conclusions.235 Therefore, a selection of high-risk patients to screen 
must be made. This was also our aim in paper III.  
For the purpose of screening stroke patients for underlying cancer, various factors 
have been suggested; laboratory tests, specific DWI findings or a combination of 
these. 
 
Laboratory tests studied as cancer-screening in ischemic stroke patients: 
- CRP > 20 210 
- Fibrinogen > 600 19, 210 
- D-dimer > 5.5 mg/dL 228 
- Hemoglobin < 12.8 g/dL236 
 
Increased D-dimer level is a direct measure of activated coagulation and has been 
used and seen as a sign of hypercoagulability in patients suffering both stroke and 
cancer.217 
The basis for increased CRP as a predictor is that cancer activates release of 
cytokines and other pro-inflammatory substances. Similarly, long-term inflammation 
as a result of underlying cancer is a cause of decreased Hb. 
 
MRI-DWI lesions: 
Suffering multiple acute cerebral infarctions (MACI) is associated with cancer.219, 228 
In NORSTROKE, 11.0 % of all patients with active cancer had acute DWI lesions in 
multiple vascular territories, while only 5.4 % of stroke patients with no history of 
cancer had multiple vascular territories affected.  
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It has also been postulated that certain MACI patterns on DWI-MRI, or MACI in 
correlation with laboratory tests can be used to screen for occult cancer.228 MACI are 
associated with strokes form embolic sources, which can be a result of cancer-
induced hypercoagulability.  
 
Imaging example 1. DWI patterns in stroke patients with cancer 
 
Images from Schwarzbach et al., with permission under the Creative Commons Attribution-Non 
Commercial-No Derivatives 4.0 International License, Cerebrovasc Dis Extra, 2015.216 The final, 
published version of this article is available at https://doi.org/10.1159/000439549 
 
Schwarzbach et al. show common DWI patterns in stroke patients with cancer 
(Imaging example 1); picture MACI with and without scattering of emboli as 
compared to single acute lesions (a). a Single acute lesion. b Multiple acute lesions in 
one vascular territory with (micro-) embolic scattering of infarction. c Multiple acute 
lesions in >1 vascular territory (bihemispheric anterior circulation lesions) without 
(micro-) embolic scattering of infarction. d Multiple acute lesions in >1 vascular 
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territory (bihemispheric anterior circulation lesions) with (micro-) embolic scattering 
of infarction. e Multiple acute lesions in >1 vascular territory (anterior and posterior 
circulation lesions) with (micro-) embolic scattering of infarction.216 
 
While MACI can result from a number of etiologies like endocarditis, PFO, myxoma 
and others, it is often occurs in relation to both AF and cancer. Therefore, Ito et al., 
suggested using concomitant D-dimer above 2.0 μg/mL and MACI to indicate 
cancer-associated stroke, despite presence of AF.237  
Also Kassubek et al. suggested using laboratory results in combination with MACI to 
detect active cancer. However, by use of AUC-ROC curves their decided screening 
involved increased CRP, granulocytosis, increased lactate dehydrogenase and 
presence of MACI.226 
 
CT thorax: 
Lung cancer is one of the cancer types believed to have an especially strong 
association with hypercoagulability. Therefore, Bentsen et al. investigated whether all 
ischemic stroke patients should be screened for lung cancer with a CT thorax during 
the stroke work-up. They concluded that the incidence of occult lung cancer in their 
stroke population was 1.1 % and that this did not warrant CT screening of all stroke 




Management of thromboembolic events in patients with active cancer 
Secondary prophylaxis 
We know that cancer is an independent risk factor for ischemic stroke, a 
thromboembolic event (TEE). Thus it is tempting to ask if cancer patients should be 
prophylactically treated with anticoagulants. However, the use of anticoagulants in 
cancer patients is a continuous balancing act between the risk of hemorrhage and the 
risk of thromboembolism.238 Nevertheless, TEEs in cancer patients are strongly 
associated with increased mortality and remain the second most common cause of 
death in oncological patients,239 thus preventing TEE can be crucial.  
For prevention of venous TEEs in cancer patients, such as DVT and pulmonary 
embolism, low-molecular weight heparin (LMWH) has been the recommended 
treatment.240, 241 Jang et al. compared enoxaparin, a LMWH, to warfarin for 
secondary prevention of cancer-associated strokes specifically, and found that 
LMWH was more effective in TEE prevention.242  
At Haukeland University Hospital, primary prophylaxis with anticoagulation is not 
common in cancer patients (unless AF is known or diagnosed). As per guidelines, the 
LMWH agent Fragmin (Dalterparin), is instigated as secondary prophylaxis if a TEE 
occurs.  
Treating cancer patients with oral anticoagulants is difficult due to their changed 
metabolism and interactions with other drugs.229 Warfarin is therefore undesirable, 
especially as it takes time to reverse the effect in case of a hemorrhagic event.  
As Fragmin is administered subcutaneously by use of syringes, it affects the quality 
of life. Therefore, oncologists believe that the threshold for anticoagulation in cancer 
patients might be lowered if medications could be administered orally.  
The Direct Oral Anticoagulant (DOAC) Apixaban, (Eliquis ®), is now investigated 
for use in cancer patients in a multi-center trial in Norway. Previous, smaller studies 
have shown that DOACs in cancer patients lead to fewer hemorrhages while 
remaining efficient in preventing TEE.240, 243 
A recent New England study also showed that edoxaban, (Lixiana ®), a novel direct 
factor Xa inhibitor, is non-inferior to Fragmin in preventing cancer-associated venous 
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TEE,244 signaling that we will likely see increased use of DOACs in cancer patients in 
the future. 
 
Intravenous thrombolysis for cancer patients with acute stroke 
The guidelines for treatment of cancer patients with intravenous (IV) tPA are unclear. 
This is because many of the major trials investigating tPA-efficacy excluded patients 
with cancer.245 
To date, the largest study on IV tPA in cancer patients is a brief report by Murthy et 
al. published in Stroke in 2013.246 This report was a retrospective study based on 
ICD-10 codes and included 150.000 stroke patients, where the use and safety of IV 
tPA in cancer patients was studied. This study concluded that there was no increase in 
IV tPA complications (ICH) for patients with cancer-associated stroke. However, 
another finding was that there were significantly fewer cancer patients that received 
treatment with IV tPA compared to other stroke patients.246 
In the NORSTROKE population included in paper III, only 4.0 % of the patients 
diagnosed with cancer prior to stroke received IV tPA treatment for their acute stroke. 
In the control group of patients with no history of cancer, 16.7 % were treated with 
IV tPA. This discrepancy could be indicative of physicians being hesitant to treat 
cancer patients due to risk or fear of hemorrhage. Graus et al. postulated that cancer 
patients generally have strokes with more diffuse symptoms,103 however, this was not 
the case for the NORSTROKE patients, where the median NIHSS on admission was 
similar in patients with and without cancer. On the contrary, in paper I we saw that 
patients with colorectal – and lung cancer had a significantly higher NIHSS on 
admission. These analyses were not adjusted for age or other potential confounders. 
Despite the high number of patients, the short report by Murthy et al. should be 
interpreted with caution given its retrospective nature. A more recent study showed 
that ischemic stroke patients with active cancer treated with IV tPA had a poorer 
clinical outcome than non-cancer stroke patients treated, especially if they had 
cryptogenic strokes. This study, however, only included 12 patients.247 
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Methodological considerations 
Handling the Inevitable Errors 
In any epidemiological study, two types of error have to be kept in mind: “systematic 
errors” and “random errors”. The random errors are the factors that are hard to adjust 
for as they naturally occur in any sample or population by chance. Random errors are 
diminished with an increase in study size. Nevertheless, one would need an infinitely 
large study size to completely eliminate them.   
The term systematic error 
is often used 
interchangeably with the 
term bias. The bias can lie 
within the researcher or 
be a systematic error, 
such as selection bias 
when selecting study 
subjects.  
In our studies, the size of 
the study population varied through studies I-III. In study III where the group of 
patients with active cancer was quite low, the chance of random errors affecting the 
results is quite high. This warrants caution when transferring the findings on to other 
study populations, or in our study specifically, to implement the findings in clinical 
use. Selection bias in determining study subjects was avoided by default, as the study 
hypotheses were not shared with the clinicians collecting and registering the 
NORSTROKE data. One could however suspect that there is a “healthy worker 
effect”248 in certain factors that are investigated. For instance, in study III, the number 
of infarctions shown on DWI MRI is compared between stroke patients with active 
cancer at the time of ictus and stroke patients with no cancer. In cases where CT 
shows massive infarction at the time of admittance, or the patients has a non-
compatible pacemaker for MRI, MRI is not performed. In such an instance, one 
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might miss large or multiple infarctions in the MRI data of the sickest patient group. 
If so, the control group is thereby healthier than the analyses can portray.   
 
The confounders of CVD risk factors 
Another factor to be kept in mind in epidemiological studies is that of confounding.249 
In the present study we were, inter alia, searching for associations between cancer 
and subsequent stroke, aiming to uncover independent risk factors of cancer-related 
stroke to use for prediction. A confounder is a hidden factor that can lead to 
misleading results through correlation with both the dependent and the independent 
variable being studied.250  
In our papers, age can be a confounder in the analyses of cancer-related stroke. Age is 
associated with both the exposure, cancer, and the outcome of ischemic stroke. To 
prevent this confounder distorting our results, we adjusted for age in all multivariate 
analyses. Smoking is also a shared risk factor of stroke and cancer, therefore this was 
also forced into all regression models in papers I-III.  
To adjust for all confounders is, however, impossible, especially in the field of NCDs 
and CVDs with their intricate and combined risk factors.  
To illustrate this, we can once more use smoking as a starting factor in a fictive 
patient. It is well known that smoking can cause inflammation and atherosclerosis, 
and as such cardiovascular disease.251 Moreover, smoking can also cause 
hypertension, an independent risk factor leading to stroke. Hypertension in a patient 
with atherosclerosis increases the risk of stroke further. Smoking may also cause lung 
cancer; another independent risk factor for stroke. If the fictive cancer patient is 
hypertensive or obese, the risk of stroke is yet again higher. Also, consumption of red 
meat has been linked to a higher risk of death from both stroke and cancer. There is a 
linear relationship between increased risk of dying from both stroke and cancer, and 
red meat consumption.82  How do we control for meat eating in our patient with 
cancer-related stroke? The answer is that we cannot control for all confounders and 
risk factors, neither clinically, nor statistically.  
79 
Finally, there are socioeconomic factors and thus social determinants of health that 
come in to play in all levels of health – none necessarily controllable by the good will 





General strengths and limitations 
The strengths of the present study are in large based on the high quality data of the 
NORSTROKE registry. Thanks to the prospective data registration, the data are 
reliable. None of the personnel in the Stroke Unit was privy to the present thesis’ 
aims while obtaining patient information or in the following registration. 
The registry uses a de facto community-based methodology, and includes patients 
from a well-defined area of about 250.000 inhabitants. This increases the strength and 
transferability of the population findings. Another strength of the study is the quality 
assurance of the cancer data, provided by linking NORSTROKE to the Cancer 
registry of Norway. This gives us the certainty that no known cancer diagnoses were 
missed for the patients included in the studies.  
The value to conducting epidemiological research in a country like Norway is the 
grateful fact that every citizen has equal access to healthcare. In comparison, several 
of the larger studies from the US are based on ICD-codes. And when 20 % of the 
population does not have health insurance, the transferability of the results to a 
general population is not necessarily viable. In a private health care system there is 
also increased risk of selection bias since socioeconomic factors likely will decide 
who can afford to purchase health insurance. 
There are limitations to the studies in the present thesis as well. Firstly, it would have 
been valuable to have data on cancer treatment and cancer stages. This is because 
hypercoagulability can be amplified with metastasis. Also, chemotherapy and 
radiation can increase risk of stroke. Moreover, other medications used, in addition to 
chemotherapy, would have been interesting to include since for instance statins can 
affect the cancer and stroke-related mortality. Another important limitation is the low 
number of cancer patients in studies II and III. This is hard to compensate for, but 
higher numbers would possibly have affected the statistical findings and the 
transferability to larger populations.  
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Cancer associated stroke- future perspectives 
We expect that in the future there will be increased awareness of the risk of cancer-
associated stroke. This will likely lead to detection of more cancer in the Stroke Unit, 
and that at an earlier stage. We recommend considering cancer as a possible etiology 
in young patients with a history of smoking and signs of hypercoagulation.  
We suggest a less restrictive use of IV tPA in cancer patients. Given the 
hypercoagulability in cancer patients, one could speculate whether they have 
increased efficacy of IV tPA because they have fibrin rich clots.  
I believe we will see new developments in the new fields of CVD and NCDs. 
It has been shown that monoclonal antibodies in patients with known CVD and 
increased CRP reduced the rate of recurrent CVD events significantly, and that 
patients who suffered from cancer while receiving the monoclonal antibody had a 
significantly lower mortality, especially in those with lung cancer.252  
Given the shared risk factors for CVD and cancer, uncovering the biological overlap 
of the pathogeneses of these two disease entities can not only give us new medical 
treatments, but furthermore serve as potential for more efficient preventative 
strategies.67  
It is not unlikely that we will also see traditional medical therapies, like statins and 
aspirin, used more frequently to modify inflammation as a key component in CVD 
and cancer development simultaneously.10  
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Conclusions  
I: We showed that the prevalence of prior cancer is increased in the stroke population 
compared to the general population of Western Norway, especially for those below 
the age of 70. The outcome of stroke patients with prior cancer was poorer than in 
stroke patients with no history of cancer, and for an ischemic stroke patient with prior 
cancer, the risk of death was doubled.  
 
II: We showed that the most common cancer types diagnosed post stroke are lung 
cancer, prostate cancer, breast cancer and colorectal cancer. The cancer types with the 
shortest median time from stroke ictus to cancer diagnosis were colorectal cancer, 
followed by lung cancer. These could have been underlying at stroke ictus. Routine 
investigation for occult cancer in all ischemic stroke patients seems unwarranted. 
However, in younger patients with increased CRP and D-dimer and a history of 
smoking, underlying cancer should be considered.  
 
 
III: We showed that the prevalence of active cancer in our stroke population was 5 %. 
In order to predict active cancer in ischemic stroke patients, a score comprising 
increased D-dimer (> 3 mg/L), lower Hb (< 12.0 g/dL) and a history of current or 
previous smoking was constructed to select patients for screening of cancer. This 
score was feasible for patients below the age of 75.  
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Appendix 
1. Trial of Org in 10172 in Acute Stroke Treatment (TOAST) 
2. National Institutes of Health Stroke Scale (NIHSS) 
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Prior Cancer in Patients with Ischemic Stroke: The Bergen
NORSTROKE Study
Henriette A. Selvik, MS,*† Lars Thomassen, MD, PhD,*† Nicola Logallo, MD, PhD,†
and Halvor Næss, MD, PhD†
Background: To compare the prevalence of prior or on-going cancer in patients with
ischemic stroke and in the general population. We hypothesized that cardioembolic
stroke is the most common stroke etiology in patients with prior cancer and that the
outcome for ischemic stroke patients (ISP) with prior cancer is poor.Methods:All ISP
registered in the Norwegian Stroke Research Registry (NORSTROKE) as part of the
ongoing Bergen NORSTROKE Study were included. Stroke etiology was deter-
mined by the Trial of Org 10172 in Acute Stroke Treatment criteria, and the severity
of the stroke was defined from the National Institutes of Health Stroke Scale score.
Information about prior or ongoing cancer disease and type was retrospectively ob-
tained from the medical patient record and The Cancer Registry of Norway. The
prevalence of cancer among stroke patients was compared with the prevalence of
cancer in the general population. Results: Among 1456 ISP, 229 (15.7%) patients
had 1 or more cancer diagnoses before the stroke. The prevalence of cancer was
higher among stroke patients compared with the general population (P 5 .001).
The most common cancer types were colorectal cancer (20.2%), prostate cancer
(15.6%), breast cancer (12.7%), cancer of the urinary tract system (10.3%), gynecolog-
ical cancer (6.2%), and lung cancer (4.5%). Logistic regression analysis showed that
patients with prior cancer had cardioembolic strokes at a higher rate (P 5 .03).
Conclusions: The prevalence of prior cancer is higher in ISP than in the general pop-
ulation. ISPs with prior cancer are more prone to cardioembolism. Key Words:
Stroke—ischemic stroke—embolic—cancer—prothrombotic—etiology—stroke risk
factors—outcome.
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Introduction
A connection between cancer and thromboembolic epi-
sodes was first recognized by Armand Trousseau in 1865
and has been debated ever since.1 Some studies suggest
that stroke occurs more frequently in cancer patients
than in the average population and that stroke is the sec-
ond most common finding overall at autopsy in patients
with cancer, after metastasis of the primary tumor.2 Ac-
cording to autopsy studies, up to 15% of cancer patients
may experience a thromboembolic event during their clin-
ical course,3 although more recent clinical studies have
shown a lower occurrence of cancer-associated stroke.4,5
Cancer can lead to stroke through various biologic
mechanisms. Solid tumors and hematologic cancer affect
the vascular system by direct tumor effect or through
coagulation disorders.2,6 Cancer and its treatment may
lead to a hypercoagulable state, causing stroke.3,7 Cancer
and stroke may also share similar risk factors. Stroke can
also occur because of cancer-associated infections.2 For pa-
tients with stroke and cancer, outcome may be poor.8
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Further understanding of factors causing stroke in
cancer patients is important for stroke prevention and
treatment in this population. The aim of this
community-based study was to assess the prevalence of
prior cancer in patients with ischemic stroke, their prog-
nosis, the most common cancer and stroke subtypes,
risk factors, and the cancer’s possible involvement in
stroke pathogenesis. We hypothesized that cardioembolic
stroke is common in patients with prior cancer and that
outcome is poor. Hypercoagulable states cause ischemic
stroke more frequently by cardioembolic mechanisms
than other pathophysiologic mechanisms such as athero-
sclerosis.4
Methods
All consecutive patients with acute ischemic stroke (the
index stroke) admitted to the stroke unit, Department of
Neurology, Haukeland University Hospital, between Feb-
ruary 2006 and August 2011 were prospectively regis-
tered in a database (The Bergen NORSTROKE Registry).
We obtained written informed consent from all patients.
The stroke unit at Haukeland University Hospital serves
a well-defined region ofz250,000 people. Ischemic stroke
was defined in accordance to the Baltimore–Washington
Cooperative Young Study Criteria as neurologic deficit
lasting more than 24 hours or transient ischemic attacks
where computed tomography or magnetic resonance im-
aging showed infarctions related to the clinical findings.9
The stroke severity was assessed by the National Insti-
tutes of Health Stroke Scale (NIHSS) on admission. The
minimum score is 0, whereas the maximum score of
a stroke with high severity is 42. Short-term functional
outcome was determined by the modified Rankin Scale
(mRS) score 7 days poststroke onset (or on discharge if
earlier than 7 days). On admission, blood pressure, C-re-
active protein, D-dimer, fibrinogen, gamma-GT, hemoglo-
bin, blood glucose, and ALAT were registered.
Electrocardiogram and duplex of the carotid arteries
were obtained. Holter monitoring was performed in se-
lected patients. The Trial of Org 10172 in Acute Stroke
Treatment criteria were used to determine the cause of
stroke by the admitting physician.10 These criteria are
used to classify 5 causes of stroke (large-vessel diseases,
cardiac embolism, small-vessel disease, other etiology,
and unknown etiology). This physician was blinded to
the study hypothesis. The patients’ medical history and
radiological images were also obtained.
Registered stroke risk factors included hypertension,
atrial fibrillation (AF), diabetes mellitus (DM), angina
pectoris (AP), acute myocardial infarction (AMI), periph-
eral artery disease, and tobacco use. Hypertension, AP,
AMI, and peripheral artery disease were considered pres-
ent if diagnosed by a physician any time before onset of
the stroke. DM was defined as treatment with glucose-
lowering medications or diet before admission. AF was
defined as chronic or paroxystic AF confirmed by electro-
cardiogram before the stroke.
The medical records were searched for prior diagnoses
of cancer. Thereafter, the Cancer Registry of Norway was
searched for prior diagnoses for assuring data quality.
The Cancer Registry of Norway was established in 1951,
and registration of all cancer cases in Norway is manda-
tory; therefore, it is a reliable source of cancer data. The
patient’s social security number was used to identify the
cancer diagnoses; thus, all the patients remained unique
and were not counted more than once. The date of diag-
nosis, cancer type, and histology were noted. The preva-
lence rates of cancer in the general population in the
community served by Haukeland University Hospital
by December 31, 2009, were obtained from the Cancer
Registry of Norway. Patients with cancer diagnosed after
admission were excluded from this study. Twenty-nine
patients with a history of nonmelanoma skin cancer be-
fore stroke were also excluded.
The study was approved by the Norwegian Regional
Ethics Committee.
Statistics
The ischemic stroke patients (ISP) were dichotomized
as ISP who had prior diagnosis of cancer (cancer-ISP)
and the ISP who had no diagnosis of cancer (noncancer-
ISP). Student t test and chi-square analyses were used
for the univariate analyses of differences between the 2
groups and between the group of noncancer-ISP and the
6 subgroups of the most common types of cancer. Logistic
regression analysis with cancer-ISP versus noncancer-ISP
as the dependent factor was used to determine indepen-
dent variables associated with cancer. Cox regression
analysis was used to investigate survival. Statistical soft-
ware Stata 12.0 was used for the statistical analyses.
Results
Among 1456 patients with ischemic stroke, 229 (15.7%)
patients had 1 or more cancer diagnoses before the stroke.
Prevalence of Cancer in Ischemic Stroke Patients and the
General Population
Figure 1, A-C shows the distribution of cancer preva-
lence among the 10-year age groups and 1 group of the
younger patients aged 15-49 years in cancer-ISP and in
the general population. Comparing all cases of prior can-
cer, the prevalence of cancer was higher in cancer-ISP
than in the general population (P5 .001). This was signif-
icant in the age groups of 15-49, 50-59, and 60-69 years.
However, in the patients with cancer diagnosed 5 years
or less before ictus, prevalence was higher only in
cancer-ISP in the age groups of 15-49 and 50-59 years
(P , .001). For patients with cancer diagnosed 1 year or
less before ictus, cancer prevalence was significantly
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higher in the same age groups as when comparing all
cases of prior cancer (both P # .001).
Patient Characteristics
The most common cancer types were colorectal cancer
(22.5%), prostate cancer (16.7%), breast cancer (13.7%),
cancer of the urinary tract system (11.0%), gynecological
cancer (6.6%), and lung cancer (4.9%). Twenty (8.7%) pa-
tients had 2 cancer diagnoses and 2 (.9%) patients had 3
cancer diagnoses. Table 1 shows characteristics of
cancer-ISP and noncancer-ISP before ictus. The mean
age was higher in cancer-ISP than for noncancer-ISP
(P , .001). The median NIHSS score on admission was
higher in cancer-ISP than in noncancer-ISP (P 5 .001)
(Table 2). Cancer-ISP had a higher frequency of chronic
AF (P , .001), heart disease (P 5 .01), and ex- or current
smoking (P 5 .008). The mean blood levels of fibrinogen
were higher in cancer-ISP than noncancer-ISP (mean 4.0
[SD 1.1] versus mean 3.7 [SD .9], P , .001). Mean blood
levels of D-dimer were similar in the 2 groups (mean 1.8
[SD 2.7] versus mean 1.4 [SD 2.4], P 5 .06).
The frequency of prior ischemic stroke was similar in
the 2 groups, yet during the hospital stay, more of
cancer-ISP had a recurrent ischemic stroke (n 5 3 [1.3%]
versus n 5 4 [.3%] in noncancer-ISP, P 5 .05). These 3
cancer-ISP had breast, prostate, and lung cancer, respec-
tively. The cancer-ISP had 21 types of cancer: colorectal
cancer (n 5 55, 22.4%), prostate cancer (n 5 42, 17.1%),
breast cancer (n 5 31, 12.7%), cancer of the urinary tract
system (n 5 28, 11.4%), malignant melanoma (n 5 17,
6.9%), gynecological cancer (n 5 16, 6.5%), lung cancer
(n 5 12, 4.9%), metastasized cancer of unknown primary
site (n 5 8, 3.3%), stomach cancer (n 5 6, 2.4%), non-
Hodgkin lymphoma (n 5 5, 2.0%), cerebral cancer
(n 5 5, 2.0%), carcinoma in situ (n 5 4, 1.6%), pancreatic
cancer (n 5 4, 1.6%), testicular cancer (n 5 3, 1.2%), gall-
bladder cancer (n 5 2, .8%), lymphoma (n 5 2, .8%), lar-
ynx cancer (n 5 2, .8%), thyroid cancer (n 5 1, .4%),
liver cancer (n 5 1, .4%), and myelomatosis (n 5 1,
.4%). Thirty-seven cancer diagnoses not in NORSTROKE
or the patient records were discovered in the Cancer Reg-
istry of Norway.
Stroke Etiology
Table 2 shows stroke etiology according to the Trial of
Org 10172 in Acute Stroke Treatment criteria. Cardioem-
bolic strokes were more common in cancer-ISP compared
with noncancer-ISP (P5 .016). On logistic regression, can-
cer before stroke was independently associated with
higher age (P , .001), cardioembolic stroke (P 5 .03),
and having smoked (P , .001). Adding blood fibrinogen
levels to the logistic regression analysis showed that prior
Figure 1. (A) Comparison of cancer prevalence in ischemic stroke patients and the general population of Western Norway in separate age groups.
(B) Comparison of cancer prevalence in ischemic stroke patients and the general population of Western Norway in separate age groups within the last 5 years.
(C) Comparison of cancer prevalence in ischemic stroke patients and the general population of Western Norway in separate age groups within the last year.
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cancer was associated with elevated fibrinogen level
(P 5 .013), whereas cardioembolic origin was no longer
associated with prior cancer (P 5 .096).
Short-term Outcome
As defined by mRS on day 7, cancer-ISP had a poorer
outcome than noncancer-ISP (P 5 .003) (Table 2).
Cancer Types
Table 3 shows a comparison between noncancer-ISP
and the 6 subgroups of the most common cancer types.
Among the 6 subgroups, lung cancer patients had the
highest median NIHSS score (P , .001). Patients with co-
lorectal cancer also had a higher median NIHSS score on
admission compared with noncancer-ISP (P # .05). Both
lung and colorectal cancer patients had a higher median
mRS on day 7 (both P 5 .05). Time from cancer diagnosis
to stroke ictus varied among the 6 most common cancer
types. Lung cancer patients had the shortest time from di-
agnosis with a median time of .78 years. The other time
intervals were 3.6 years in prostate cancer patients,
6.7 years in colorectal cancer patients, 7.8 years for both
patients with cancer of the urinary tract system and breast
cancer, and 17.7 years for gynecological cancer patients.
Median follow-up time for all patients after ischemic
stroke ictus was 3.8 years (interquartile range 2.6-
4.8 years). On Cox regression analysis, age, sex, prior can-
cer, DM, AMI, prior smoking, and high NIHSS score on
admission were associated with long-term mortality
(Table 4). Prior cancer was associated with a doubled
risk of death (P , .001).
Discussion
In the present study 15.7% of our ISP had prior cancer.
This is similar to what was found in an autopsy study
(15%) in 1985.3 However, in a clinical study of cancer pa-
tients, only 3.5% of their cancer patients experienced
stroke after their cancer was diagnosed.11 The difference
between this study and the present study may be be-
cause of different study design or that we were able to
disclose more patients with prior cancer because of
obligatory reporting to the Cancer Registry of Norway.
Yet, another more recent study of cancer patients that
Table 1. Patient characteristics in ischemic stroke patients with and without prior cancer before stroke
Cancer diagnosis before index
stroke, N 5 229
Stroke patients with no history
of cancer, N 5 1227 P
Male, n (%) 124 (54.1) 694 (56.6) .5
Female 105 (45.9) 533 (43.4)
Age, mean (SD) 76.1 (11.1) 69.5 (15.1) ,.001
Prior ischemic stroke, n (%) 36 (15.7) 169 (13.8) .4
Stroke during hospital stay 3 (1.3) 4 (.3) .05
Hypertension 127 (55.5) 619 (50.5) .2
Atrial fibrillation, chronic 33 (14.4) 88 (7.2) ,.001
Atrial fibrillation, paroxysmal 24 (10.5) 107 (8.7) .4
Diabetes mellitus 30 (13.1) 170 (13.9) .8
Acute myocardial infarction 39 (17.0) 163 (13.3) .1
Heart disease 37 (16.2) 124 (10.1) .01
Ex- and current smoking 141 (61.6) 664 (54.1) .008
Table 2. Patient characteristics in ischemic stroke patients with and without prior cancer poststroke
Cancer diagnosis before index
stroke, N 5 229
Stroke patients with no history
of cancer, N 5 1227 P
NIHSS, median (IR) 5 (2-12) 3 (1-8) .001
mRS, day 7 2 (1-4) 2 (1-4) ,.001
TOAST, n (%) .02
Atherosclerosis 26 (11.4) 150 (12.2)
Cardioembolic 89 (38.9) 349 (28.4)
Small-vessel disease 23 (10.0) 175 (14.3)
Other 3 (1.3) 35 (2.9)
Unknown 87 (38.0) 516 (42.1)
Abbreviations: mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IR, interquartile range; TOAST, Trial of Org
10172 in Acute Stroke Treatment.
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had ischemic strokes found that 26% of the strokes were
defined as ‘‘cancer-associated ischemic strokes.’’12 In that
study, strokes were defined as cancer-associated strokes
in all cancer patients whom were undergoing treatment
while presenting with elevated fibrinogen and D-dimer
levels.
In the present study, the prevalence of prior cancer in
stroke patients was higher than in the general population
for all age groups, especially among patients younger
than 70 years. This suggests that cancer may be an inde-
pendent cause of stroke or that cancer and stroke have
common risk factors. Also, there may be unknown risk
factors that predispose patients to both stroke and cancer.
Median time from cancer diagnosis to stroke ictus
among our patients was 6.8 years. We have found now
comparable data in the literature. However, in a clinical
study of stroke patients with stroke as an initial presen-
tation of cancer, 83.3% had a second stroke within
4 months of their index stroke.5 This indicates that time
to stroke is short with an on-going cancer disease,
whereas the long time interval from cancer diagnosis to
stroke in our patients is likely because of high frequency
of cured cancer.
Colorectal cancer, prostate cancer, breast cancer, cancer
of the urinary tract system, gynecological cancer, and
lung cancer were the most common cancer types in our
study. Other studies of stroke patients with history of can-
cer showed that lung and breast cancer were the most
common types of cancer,4,5 where lung cancer was the
most frequent of the 2.4 In our study, breast and lung can-
cer were, respectively, the third and fifth most common
cancer types. The discrepancy with previous studies
may be because of the short time from cancer diagnosis
to stroke ictus (median 284.5 days or .78 years) among
our patients with lung cancer. Different study design
and poor prognosis of lung cancer may explain this dis-
crepancy. The community-based approach in the present
study suggests that our results are more realistic.
Lung cancer patients had a worse outcome despite
their mean age being lower than the other cancer groups
and stroke patients without cancer. A significantly higher
number of the lung cancer patients were deceased 7 days
postictus, compared with the other groups of cancer.
We confirmed the hypothesis of cardioembolic strokes
being the most common stroke etiology in the ISP with
prior cancer. This has also been shown in previous stud-
ies.4,13 Comparing stroke etiology between the most
common types of cancer and the noncancer-ISP, only the
colorectal cancer stroke patients had a significantly higher
number of strokes because of cardiac embolism. It is pos-
sible that some strokes were caused by a cancer-induced
hypercoagulable state. Hypercoagulable states cause
















Age, mean (SD)* 69.5 (15.1) 78.6 (10.3y 76.2 (9.1)z 75.5 (12.5)z 75.5 (10.4)z 76.1 (10.1) 67.2 (11.8)
Male, n (%) 694 (56.6) 32 (13.4) 42 (18.3) — 25 (10.9)y — 5 (2.2)
NIHSS, median (IR) 3 (1-8) 5 (1-14)z 4 (2-7) 4 (3-12) 3 (1-7) 5 (3-10) 14 (4-19.5)y
mRS, day 7 2 (1-4) 3 (1-4)z 2 (1-3) 3 (2-4) 2 (1-4) 3 (1.5-4) 4 (2-4.5)z
Time from cancer to
index stroke, y*
— 6.7 3.6 7.8 7.8 17.7 .78
Etiology, n (%)
Cardioembolic 349 (28.4) 25 (45.5)z 16 (38.1) 10 (32.3) 8 (28.6) 4 (25.0) 3 (25.0)
Atherosclerosis 150 (12.2) 5 (9.1) 5 (11.9) 2 (6.5) 5 (17.9) 2 (12.5) 1 (8.3)
Small-vessel disease 175 (14.3) 9 (16.4) 6 (14.3) 5 (16.1) — 1 (6.3) —
Other 35 (2.9) — — — — — 1 (8.3)
Unknown 516 (42.1) 16 (29.1) 15 (35.7) 14 (45.1) 15 (53.6) 8 (50.0) 7 (58.3)
Abbreviations: mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IR, interquartile range.
*Stroke patient’s first cancer diagnosis.
yP # .001.
zP # .05.
Table 4. Cox regression analysis in ischemic stroke patients
with and without prior cancer with Hazard ratios for long-
term mortality
Hazard ratio (CI) P
Prior cancer 2.0 (1.7-2.5) ,.001
Age 1.1 (1.07-1.1) ,.001
Sex .98 (.8-1.3) .9
Diabetes mellitus 1.4 (1.0-1.97) .02
Myocardial infarction 1.7 (1.3-2.2) ,.001
Smoking 1.7 (1.2-2.3) .002
NIHSS 1.1 (1.09-1.12) ,.001
Abbreviations: CI, confidence interval; NIHSS, National Insti-
tutes of Health Stroke Scale.
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ischemic stroke more frequently by cardioembolic mech-
anisms than other pathophysiologic mechanisms such as
embolism in atherosclerosis.4 However, this is still a sub-
ject for discussion in need of further research.2
Cardioembolic mechanisms are associated with severe
stroke. Compatible to this, the cancer-ISP hadmore severe
neurologic deficits on admission and poorer short-term
functional outcome than patients without prior cancer.
This pertained specially to patients with prior lung cancer
and colorectal cancer. Others have also reported more se-
vere strokes in patients with cancer.5
An association between cancer and thromboembolic
events has been well established by numerous studies.14
The cancer and the cancer treatment can be complicated
by such events. Both venous and arterial complications,
such as stroke, are seen as cancer patients can develop
a hypercoagulable state.15 The cancer cells can affect the
coagulation cascade causing thrombin generation and
thrombosis and causing a thrombogenic surface of the
vascular lining. As cancer therapies become increasingly
aggressive, the risks of thromboembolic events in-
crease.7,16 Some chemotherapies have been shown to
increase the risk of stroke, particularly chemotherapies
used for lung and breast cancer.2,17 Small-cell lung cancer
is often treated with Cisplatin and Gemcitabine, which
yield high risk for cerebrovascular events.2,18 The
various types of chemotherapies may present different
risks, which may explain why the lung cancer patients
have poorer outcome, despite a significantly lower age.
However, the risk may also vary between various
cancer types. In patients with ovarian cancer, the
treatment as such may not necessarily cause the greatest
risk for ischemic stroke but rather the reduced ovarian
activity.19 In accordance to the varying risk depending
on cancer type, all patients with nonmelanoma skin can-
cer were excluded. The likelihood of a cancer of that
type causing a hypercoagulable state is low.
We found elevated fibrinogen and a trend toward ele-
vated D-dimer in cancer-ISP compared with noncancer-
ISP. It has previously been shown that in patients with
suspected thromboembolic disorders, fibrinogen degra-
dation products were consistently elevated in hemostatic
disorders.20 This may suggest that a hypercoagulable
state wasmore frequent in the cancer-ISP group. This pos-
sibility is also supported by the fact that ISP with prior
cancer experienced a higher number of recurrent stroke
during the hospital stay compared with the noncancer-
ISP even though the recurrence frequencies were low.
The strength of this community-based study is the high
number of unselected stroke patients included. Another
strength is that the NORSTROKE research registry was
linked to the Cancer Registry of Norway; thus, all stroke
patients with a history of cancer were registered. Aweak-
ness of our study is that we had no data neither on cancer
treatment before the index stroke nor on withdrawal
of care.
Conclusions
Prior cancer has a higher prevalence in ISP than in the
general population, especially among patients younger
than 70 years. Our study indicates that ISP with prior can-
cer are more prone to strokes with a cardioembolic origin
etiology and that outcome is poorer compared with non-
cancer-ISP.
Acknowledgment: The study has used data from the
Cancer Registry of Norway. The interpretation and reporting
of these data are the sole responsibility of the authors, and no
endorsement by the Cancer Registry of Norway is intended
or should be inferred.
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 Abstract 
 Background:  Underlying malignancy can cause ischemic stroke in some patients. Mecha-
nisms include the affection of the coagulation cascade, tumor mucin secretion, infections and 
nonbacterial endocarditis. The release of necrotizing factor and interleukins may cause in-
flammation of the endothelial lining, creating a prothrombotic surface that triggers thrombo-
embolic events, including stroke. The aims of this study were to assess the occurrence of can-
cer in patients who had recently suffered an ischemic stroke and to detect possible associations 
between stroke and cancer subtypes.  Methods: All ischemic stroke patients registered in the 
Norwegian Stroke Research Registry (NORSTROKE) as part of the ongoing Bergen NOR-
STROKE study were included. Blood samples were obtained on admission. Stroke etiology was 
determined by the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria, and the se-
verity of stroke was defined according to the National Institute of Health Stroke Scale score. 
Information about cancer disease after stroke was obtained from patient medical records and 
The Cancer Registry of Norway.  Results: From a total of 1,282 ischemic stroke patients with 
no history of cancer, 55 (4.3%) patients were diagnosed with cancer after stroke. The median 
time from stroke onset to cancer diagnosis was 14.0 months (interquartile range 6.2–24.5). 
Twenty-three (41.8%) patients were diagnosed with cancer within 1 year and 13 (23.6%) with-
in 6 months. The most common cancer type was lung cancer (19.0%). By Cox regression anal-
ysis, cancer after stroke was associated with elevated D-dimer levels on admittance (p < 
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0.001), age (p = 0.01) and smoking (p = 0.04).  Conclusions:  Cancer-associated stroke is rare, 
and routine investigation for cancer seems unwarranted in acute ischemic stroke. However, in 
stroke patients with elevated levels of blood coagulation factors, C-reactive protein, higher 
age and a history of smoking, underlying malignancy should be considered. Our study sug-
gests that an unknown stroke etiology does not predict malignancy. 
 © 2015 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 A link between cancer and stroke has long been recognized  [1] . Some studies suggest that 
stroke, in some cases, is caused by underlying malignancy  [2, 3] . Mechanisms include the 
affection of the coagulation cascade, tumor mucin secretion, infections and nonbacterial 
endocarditis  [4] . The release of necrotizing factor and interleukins may cause inflammation 
of the endothelial lining, creating a prothrombotic surface that triggers thromboembolic 
events, including stroke  [5, 6] . Elevated D-dimer and fibrinogen levels can indicate a cancer-
induced prothrombotic state  [7, 8] . Elevated C-reactive protein (CRP) may represent cancer-
mediated inflammation  [9] . Cancer patients are at an increased risk of stroke, especially 
within 1 year of cancer proliferation  [10] . Though rarely, ischemic stroke has been seen as 
the first sign of underlying malignancy  [7, 10] .
 The aims of this community-based study were to assess the occurrence of cancer in 
patients who had recently suffered an ischemic stroke. We hypothesized that some of the 
patients had an underlying malignancy at stroke onset, which contributed to a cancer-asso-
ciated stroke. We also aimed to detect possible associations between stroke and cancer 
subtypes.
 Methods 
 Study Design 
 All patients admitted to the Department of Neurology, Haukeland University Hospital, 
Bergen, Norway, with confirmed ischemic stroke were prospectively included in the 
Norwegian Stroke Research Registry (NORSTROKE) as part of the Bergen NORSTROKE study.
 Ischemic stroke was defined in accordance to the Baltimore-Washington Cooperative 
Young Study Criteria as neurologic deficit lasting >24 h or transient ischemic attacks where 
CT or MRI showed infarctions related to the clinical findings  [11] .  The severity of the stroke 
was assessed by the National Institute of Health Stroke Scale (NIHSS) on admittance. Short-
term outcome was determined by the modified Rankin Scale (mRS) score 7 days after stroke 
onset (or on discharge if the patient was discharged earlier than after 7 days). On admission, 
vital parameters and blood analyses were obtained. Clinical characteristics were registered 
by a neurologist <1 day after admission. Investigations included electrocardiogram, Duplex 
and transthoracic echocardiography or transesophageal echocardiography. The Trial of Org 
10172 in Acute Stroke Treatment (TOAST) criteria were used to determine the cause of stroke 
 [12] .
 Stroke risk factors including hypertension, atrial fibrillation (AF), persistent foramen 
ovale, diabetes mellitus, angina pectoris, coronary artery disease and tobacco use were regis-
tered. Hypertension, angina pectoris, acute myocardial infarction, peripheral artery disease 
and chronic or paroxystic AF were considered present if diagnosed by a physician any time 

























   
   
   
   
   
   





















109Cerebrovasc Dis Extra 2015;5:107–113
 DOI: 10.1159/000440730 
E X T R A
 Selvik et al.: Cancer-Associated Stroke: The Bergen NORSTROKE Study 
www.karger.com/cee
© 2015 The Author(s). Published by S. Karger AG, Basel
 The study period started in February 2006 and ended on September 15, 2011. Study end 
points were September 15, 2011, or the date of death. Cancer data was obtained from the 
ischemic stroke patients (ISP) medical records and the Cancer Registry of Norway.
 The study was approved by the Norwegian Regional Ethics Committee.
 Statistics 
 The patients formed two groups; the ISP who were diagnosed with a new diagnosis of 
cancer after stroke onset (cancer-ISP) and the ISP who had no history of cancer (non-cancer-
ISP) before or after stroke. Student's t test and χ 2 analyses were used for the univariate 
analyses when appropriate. The Cox regression model was applied for multivariate analyses, 
and the statistical software Stata 13.0 was used for the statistical analyses.
 Results 
 From a total of 1,282 patients with confirmed ischemic stroke, 55 (4.3%) patients had 
one or two cancer diagnoses after their stroke. The mean age in the cancer-ISP group was 72.7 
years [standard deviation (SD) 11.5], and for the non-cancer-ISP group it was 69.5 years (SD 
15.1). The median follow-up time of the entire study population was 26.9 months [inter-
quartile range (IQR) 13.7–42.5], while for non-cancer-ISP alone (n = 1,227), the median 
follow-up time was 27.7 months (IQR 14.2–43.1).  Table 1 shows the baseline characteristics 
of all ISP.
 Table 1.  Patient characteristics in ISP with and without later cancer
Cancer diagnosis after
index stroke (n = 55)
ISP with no history of 
cancer (n = 1,227)
p
Male, n 34 694 0.4
Female, n 21 533
Mean age ± SD, years 72.7 ± 11.5 69.5 ± 15.1 0.1
Median NIHSS (IQR) 4 (2 – 9) 3 (1 – 8) 0.9
Median mRS (IQR) 2 (1 – 4) 2 (1 – 4) 0.4
Mean temperature on admission ± SD, °C 36.6 ± 0.8 36.6 ± 2.8 0.9
Prior ischemic stroke 13 (23.6) 169 (13.8) 0.04
Hypertension 26 (47.3) 619 (50.4) 0.7
Chronic AF 6 (10.9) 88 (7.2) 0.3
Paroxysmal AF 6 (10.9) 107 (8.7) 0.5
Diabetes mellitus 10 (18.2) 170 (13.9) 0.3
Previous myocardial infarction 6 (10.9) 163 (13.3) 0.6
Heart disease 5 (0.9) 124 (10.1) 0.8
Smoking 36 (65.5) 664 (54.1) 0.3
Blood values
Mean D-dimer ± SD, mg/l 2.7 ± 4.6 1.4 ± 2.4 0.003
Mean fibrinogen ± SD, mmol/l 4.7 ± 5.3 3.7 ± 0.9 <0.001
Mean hemoglobin ± SD, g/dl 14.0 ± 1.9 14.3 ± 1.5 0.2
Mean glucose ± SD, mmol/l 7.2 ± 2.9 6.7 ± 2.5 0.1
Mean CRP ± SD, mg/l 18.8 ± 41.2 10.0 ± 26.4 0.02
Mean cholesterol ± SD, mmol/l 5.1 ± 1.3 5.4 ± 1.3 0.1
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 Time from Index Stroke to Cancer Diagnosis 
 The median time from stroke onset to cancer diagnosis was 14.0 months (IQR 6.2–24.5). 
Twenty-three (41.8%) patients were diagnosed within 1 year, 13 (23.6%) within 6 months 
and 9 (16.4%) within 3 months after stroke onset, including 4 (7.3%) diagnosed within 1 
month. Three were diagnosed within 1 week after stroke onset with the following cancer 
diagnoses: lung cancer, prostate cancer and lymphoma. Of the patients diagnosed with cancer 
within 1 month, 2 had been diagnosed with lung cancer. Colorectal cancer (n = 4) had the 
shortest median time from stroke onset to cancer diagnosis, namely 4.0 months (IQR 1.3–22.0), 
followed by lung cancer (n = 12) with a median time from stroke onset to cancer diagnosis of 
8.7 months (IQR 5.5–27.3).
 Cancer Diagnoses 
 In total, the 55 patients had 64 cancer diagnoses, distributed among 13 different cancer 
types. The 7 most common cancer types were lung cancer (n = 12, 19.0%), prostate cancer
(n = 10, 15.9%), colorectal cancer (n = 7, 11.1%), breast cancer (n = 7, 11.1%), gynecological 
cancer (n = 5, 7.9%), lymphoma (n = 4, 6.3%) and metastatic cancer of unknown primary site 
(CUP; n = 4, 6.3%).  Table 2 describes the characteristics of the cancer subtypes. The 6 other 
types of cancer included 4 bladder, 4 gastric and 3 pancreatic cancers, 2 carcinomas in situ, 1 
malignant melanoma and 1 sarcoma.
 Smoking 
 There was no difference in smoking habits between the cancer-ISP group and the 
non-cancer-ISP control group. However, by cancer subtypes, lung cancer (p = 0.03) and 
lymphoma (p = 0.003) had a higher rate of smoking compared to non-cancer-ISP.
 Blood Samples 
 CRP was elevated in the cancer-ISP on admittance (p = 0.02). Among cancer subtypes, 
only lung cancer had increased mean CRP levels of 29.7 (SD 68.4, p  ≤ 0.05). The D-dimer level 
was elevated in the cancer-ISP on admittance (p = 0.003). Among the cancer subtypes, lung 
cancer patients had increased D-dimer levels compared to ISP with a mean D-dimer of 3.7 (SD 
6.3, p  ≤ 0.05).

















Age 69.5 ± 15.1 68.4 ± 11.2 75.2 ± 12.4 74.6 ± 14.6 76.5 ± 8.9 71.7 ± 13.7 62.4 ± 5.4 71.6 ± 12.6
Male, n (%) 694 (56.6) 6 (50.0) 10 (100.0) 5 (71.4) 1 (14.3) – 4 (100.0) 3 (75.0)
Median NIHSS (IQR) 3 (1 – 8) 5 (1 – 8) 4 (3 – 9) 3 (0 – 9) 2 (2 – 3) 5 (4 – 7) 3 (2 – 7.5) 7 (4.5 – 10)
Median mRS (IQR) 2 (1 – 4) 2 (1 – 4) 1.5 (1 – 3) 2 (2 – 4) 2 (2 – 3) 1 (1 – 1) 2 (81.5 – 2) 2.5 (1.5 – 3)
Median time from
stroke to cancer
(IQR), months – 8.7 (5.5 – 27.3) 14.0 (6.0 – 20.3) 4.0 (1.3 – 22.0) 12.2 (8.1 – 25.8) 14.3 (2.2 – 18.1) 16.8 (7.1 – 23.8) 15.9 (12.4 – 20.1)
Smoking, n (%) 664 (54.1) 10 (83.3)* 7 (70.0) 5 (71.4) 3 (42.9) 3 (60.0) 4 (100)** 2 (50.0)
Blood values
Fibrinogen, mmol/l 3.7 ± 1.1 4.0 ± 1.5 4.3 ± 1.6 9.2 ± 13.6** 4.5 ± 2.1 3.7 ± 0.4 3.6 ± 0.4 3.5 ± 0.8
Hemoglobin, g/dl 14.3 ± 1.5 13.9 ± 2.2 14.0 ± 1.9 13.5 ± 2.8 13.2 ± 2.0 13.9 ± 1.8 14.8 ± 1.3 14.1 ± 0.9
Cholesterol, mmol/l 5.3 ± 1.3 5.2 ± 1.4 5.0 ± 1.0 4.9 ± 1.5 5.0 ± 1.7 5.0 ± 1.3 5.5 ± 0.4 5.2 ± 1.4
D-dimer, mg/l 1.4 ± 2.5 3.7 ± 6.3* 1.7 ± 1.4 1.0 ± 1.1 1.8 ± 2.7 3.5 ± 4.8 – 3.0 ± 1.8
CRP, mg/l 10.0 ± 26.4 29.7 ± 68.4* 14.3 ± 33.7 12.3 ± 21.3 25.6 ± 34.8 31.6 ± 59.5 3.5 ± 2.5 3.0 ± 1.8
Glucose, mmol/l 6.7 ± 2.5 8.2 ± 4.6* 6.2 ± 1.3 6.7 ± 1.5 6.7 ± 2.8 6.5 ± 1.8 8.1 ± 2.0 6.2 ± 1.8
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 Stroke Etiology and Outcome 
 Of the 55 cancer-ISP, 21 (38.2%) had an unknown stroke etiology compared to 516 
(42.1%) of the non-cancer-ISP (p = 0.09). Cardioembolic etiology was found in 32.7% of the 
cancer-ISP and 28.5% of the non-cancer-ISP. Among cancer subtypes, lymphoma had a higher 
frequency of cardioembolic etiology (p  ≤ 0.05). The mRS score did not differ between 
non-cancer-ISP and cancer subtypes.
 By Cox regression analysis, cancer after stroke was associated with increased D-dimer 
levels on admittance (p < 0.001), age (p = 0.01) and smoking (p = 0.04;  table 3 ).
 Discussion 
 We found that malignancy was detected in few patients (0.3%) within the first month 
after acute ischemic stroke. However, several previous studies have shown that ischemic 
stroke can be the first manifestation of cancer  [2, 7, 13, 14] . One study found an underlying 
malignancy in 0.4% of their ischemic stroke patients  [7] . We found that of all ischemic stroke 
patients with no prior cancer, 1.8% were diagnosed with cancer within 1 year. It has previ-
ously been reported that mainly advanced cancers create a massive risk  [3] . For the ischemic 
stroke patients diagnosed with cancer within 6 months (1.0%), it is likely that they had an 
underlying malignancy at the time of stroke onset.
 Knowing that specific tumor types may affect the vascular system in different ways, and 
that some cancers have similar risk factors as for stroke, analyses of subtypes of cancer are 
important  [15] . Lung cancer, prostate cancer, colorectal cancer, breast cancer, gynecological 
cancer, CUP and lymphoma were the most common cancer types in our study. Prothrombotic 
states have previously been documented in cancer of the lung and colon as well as lymphomas. 
Lung cancer was overrepresented in our study, which also has been reported by similar 
studies of cancer-associated stroke  [16] . Gynecological tumors are also reported to have a 
potential for being included in ischemic stroke pathogenesis  [13] . Of the prostate cancer 
patients, 50% had an unknown stroke etiology. However, as prostate cancer is rarely 
mentioned in relation to prothrombotic state, our findings may be due to prostate cancer 
being the most common male cancer type in general and thus incidental to the stroke  [17] . 
Both lung and colon cancer have been linked to smoking  [18] . Smoking is also a risk of ischemic 
stroke and may be a confounding factor in some cancer-associated strokes.
 Of the classic risk factors for ischemic stroke, smoking was the only one associated with 
cancer. Higher D-dimer and CRP levels were associated with cancer, especially with lung cancer. 
In concordance, previous studies have also shown a higher risk for stroke in lung cancer patients 
 [19] . Increased D-dimer and CRP levels may be caused by cancer development  [8, 9] .
 The ISP with cancer were older than those in the control group. However, looking at the 
subtypes of cancer, the patients diagnosed with lung cancer and CUP were slightly younger 
than the control group. It has been shown that younger patients, below 49 years of age, often 
Hazard ratio 95% confidence
interval
p
Sex 0.68 0.3 – 1.4 0.3
Age 1.04 1.0 – 1.0 0.01
Smoking 1.59 1.0 – 2.5 0.04
D-dimer 1.13 1.1 – 1.2 <0.001
 Table 3. Cox regression analysis 


























   
   
   
   
   
   





















112Cerebrovasc Dis Extra 2015;5:107–113
 DOI: 10.1159/000440730 
E X T R A
 Selvik et al.: Cancer-Associated Stroke: The Bergen NORSTROKE Study 
www.karger.com/cee
© 2015 The Author(s). Published by S. Karger AG, Basel
have different stroke etiologies than older stroke patients; prothrombotic state is more 
common and classic risk factors such as atherosclerosis are less common  [20] .
 Stroke severity was similar between the two groups. A previous study defined stroke as 
being cancer related if stroke etiology was unknown and cancer was diagnosed within 6 
months of stroke  [10] . In contrast, we found no difference in etiology between our two groups. 
Thus, etiology may not be a predictor of cancer-associated stroke.
 A limitation to our study was that the follow-up time differed among the study subjects. 
This may have caused a possible underestimation of cancer occurrence. On the other hand, 
patients diagnosed with cancer within 6 months after stroke onset may have been under 
careful medical surveillance due to their strokes, increasing the possibility of early cancer 
detection  [16] . Because of the likelihood of stroke involvement in various cancers, it was 
necessary to study the subtypes of cancer separately. In doing so, each group consisted of a 
low number of study subjects. An advantage of the present study, as compared to previous 
studies, is the exclusion of patients with prior cancer  [19] . This eliminates the question of 
whether the cancer treatment or the malignancy itself was the potentially involved factor in 
stroke pathogenesis.
 Conclusion 
 Cancer-associated stroke is rare, and routine investigation for cancer seems unwar-
ranted in acute ischemic stroke. However, in stroke patients with elevated levels of blood 
coagulation factors, CRP, higher age and a history of smoking, underlying malignancy should 
be considered. Our study suggests that an unknown stroke etiology does not predict malig-
nancy.
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